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Abstract 
The dissemination of tumor cells to distant organs i.e. metastasis is an 
exceedingly complex process leading to 90% of all cancer deaths. Despite being so 
clinically important, little is known about this process that requires tumor cells to leave 
the primary tumor site, intravasate and transport through the blood stream, extravasate 
and colonize at secondary sites leading to distant metastases. Survivin, a member of the 
IAP (Inhibitor of Apoptosis) family with known functions in apoptosis and mitosis, is 
highly expressed in aggressive tumors and is associated with poor prognosis and adverse 
clinical outcome. But the mechanistic role of survivin in metastatic dissemination has not 
been investigated. In this study, we demonstrate an important and novel role of survivin 
in activating a broad gene expression program in tumor cells. Of particular importance is 
the upregulation of a distinct class of cell adhesion molecules, particularly fibronectin. 
This IAP mediated gene regulation requires synergistic intermolecular cooperation 
between survivin and its related cofactor molecule, XIAP that results in activation of NF-
κB dependent fibronectin gene expression. The binding of fibronectin with its cognate 
cell surface receptors initiates outside–in signaling leading to the autocrine and paracrine 
activation of cell motility kinases, FAK and Src, in turn leading to enhanced tumor 
invasion and metastasis. The importance of survivin and XIAP in the process of 
metastasis has also been demonstrated in vivo using intrasplenic injections in mouse 
models.  
Overall this study is the first to place survivin upstream of transcriptional 
activation of gene expression particularly fibronectin. In addition, it also demonstrates the 
vi 
importance of survivin-XIAP complex in mediating NF-κB activation which in turn 
switches on the expression of various target genes involved in tumor metastasis. Hence 
this study dissects the upstream and downstream requirements of survivin- XIAP 
complex mediated tumor dissemination and metastasis.   
 
Significance of this Study 
The hallmark of end-stage cancer is metastasis, an incurable condition almost 
invariably associated with death from disease.  Despite a better understanding of the 
metastatic process, and the identification of key gene expression requirements of this 
pathway, the development of anti-metastatic therapies has lagged behind, with no viable 
options being currently offered in the clinical setting. Our findings that Inhibitor of 
Apoptosis (IAP) proteins functions as metastasis-promoting genes independently of cell 
survival, but through activation of cell motility could have important ramifications for the 
broader application of IAP antagonists currently in early clinical trials, as novel anti-
metastatic therapies. 
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Chapter 1: Introduction 
 
The dissemination of tumor cells to distant organs, i.e. metastasis (Nguyen and 
Massague, 2007), heralds a nearly invariably fatal phase of epithelial malignancies, with 
few, if any, therapeutic options. Tumor metastasis is a highly complex and dynamic event 
that requires tumor cells to dissociate from the primary tumor mass and move and 
localize to distant or secondary sites (Chambers et al., 2001; Woodhouse et al., 1997). 
The essential steps in the metastatic cascade include invasion of the adjacent tissues, 
intravasation, survival in circulation when detached from the extracellular matrix, a 
condition called anoikis (Frisch and Screaton, 2001), transport in blood and lymphatic 
vessels, extravasation, colonization and growth at distant sites with unrelated 
microenvironments (Weigelt et al., 2005). To successfully complete the ‘metastatic 
journey’ cancer cells acquire distinct mechanisms and activate several gene expression 
programs and hence several models of metastasis have been proposed (Nguyen et al., 
2009). One of the models suggests that metastatic ability is an acquired event wherein the 
primary tumor cells acquire genetic alterations during the course of time and become 
more invasive and metastatic (Scheel et al., 2007). The other model proposes that the 
metastatic capacity of primary tumors is pre-determined at the onset of tumorigenesis and 
gene expression signatures exist which can distinguish localized tumors from tumors that 
metastasize to distant locations (Talmadge, 2007). Despite opposing views, one 
invariable feature of the metastatic process is deregulated gene expression (Nguyen and 
Massague, 2007). Genes that promote metastasis have been categorized into three distinct 
2 
classes based on their level of participation (Nguyen and Massague, 2007). They include 
metastasis -initiation genes that promote tumor invasion, cell motility and angiogenesis. 
The gain or loss of function of these genes allows tumor cells to invade the basement 
membrane and escape into the circulation. The second class of genes is referred to as 
metastasis-progression genes that confer a specific organ tropism. They are involved in 
functions such as vascular remodeling and provide the malignant cells the ability to 
infiltrate the distant organs. They could be enriched at the primary site but possibly have 
a unique role at the distant site. The third class is called metastasis-virulence genes that 
promote growth and colonization at distant sites. They do not affect the primary growth 
but provide selective advantage at the secondary site (Nguyen and Massague, 2007).  
Metastasis suppressors such as  caspase 8 have also been strongly implicated in tumor 
metastasis (Stupack et al., 2006) 
Section I: Steps of Metastasis 
1. Tumor Migration and Invasion 
Tumor invasion is the initial event in the metastatic cascade and is primarily mediated by 
regulated interaction of tumor cells with the surrounding extracellular matrix (ECM). 
This step of metastasis requires tumor cells to attach, proteolyze and migrate through the 
basement membrane and enter into the circulation (Fidler et al., 1978). The extracellular 
matrix is composed of both interstitial component and the basement membrane. The 
extracellular-matrix components, such as fibronectin, collagen, and Laminin, act as a 
scaffold  allowing cells to attach and move by making contacts with the cell-surface 
receptors called integrins (Chiang and Massague, 2008). As one of the most abundant 
3 
constituents of the extracellular matrix, fibronectin binds multiple integrins (Cukierman 
et al., 2002), and this binding results in the activation of focal adhesion kinase (FAK) 
(Sieg et al., 2000), Src (Yeatman, 2004), Akt (Irie et al., 2005), as well as modulation of 
the small GTPases of the Rho family (Nobes and Hall, 1995).  In response to these 
signals, cells remodel their actin cytoskeleton (Juliano et al., 2004), express matrix 
metalloproteinases (Han et al., 2006), become migratory (Livant et al., 2000), invade 
basement membranes (Gaggioli et al., 2007), and acquire the ability to resist apoptosis 
(Fornaro et al., 2003). Increased fibronectin expression has been shown in various tumor 
cell types like melanomas (Bittner et al., 2000), breast cancers (Jiang et al., 2002), and 
thyroid carcinomas (Huang et al., 2001c). Global gene expression profiling has shown 
that increased fibronectin expression leads to oncogenic transformation of melanocytes 
(Bittner et al., 2000) and tumor-derived fibronectin help melanoma cells to become more 
invasive and metastatic (Gaggioli et al., 2007). Apart from its role in tumor invasion, 
fibronectin has been shown more recently to play an important role in the colonization of 
primary tumor cells at the distant sites by forming a ‘premetastatic niche’ (Kaplan et al., 
2006).  
Integrins are heterodimeric transmembrane proteins containing 1 of 18 α- and 1of 
8 β subunits. The different α- and β chain combinations dictate the specificity for 
different ECM components (Hynes, 2002). For example, α5β1 selectively binds 
fibronectin whereas αvβ3 binds to fibronectin, vitronectin, Von Willebrand factor and  
cleaved forms of collagen and laminin (van der Flier and Sonnenberg, 2001). A number 
of studies have demonstrated that more migratory and invasive cells show dramatic 
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alterations in the levels of integrin and ECM expression. For example αvβ3 integrin 
overexpression is seen at the invasive front of malignant melanoma cells (Brooks et al., 
1994). Similarly α6β4 has been implicated in the invasion of colorectal carcinoma cells 
(Chao et al., 1996).  
Integrins form a functional link between the ECM and the intracellular signaling 
pathways that influence cell shape, motility, proliferation and migration and invasion 
(Aplin et al., 1999).  ‘Outside–in signaling’ mediated by binding of ECM (Juliano et al., 
2004) to integrins leads to the clustering of integrins that initiates several downstream 
signaling events. Since integrins lack intrinsic catalytic activity, signals initiated by 
ECM–integrin interactions are transduced inside the cells through activation of some 
non-receptor tyrosine kinases like focal adhesion kinase (FAK) and Src.  
Focal Adhesion Kinase (FAK)  
FAK is a 120 Kilodalton cytoplasmic protein tyrosine kinase that co-localizes 
with integrins to structures referred to as ‘focal contacts’(Parsons, 2003). Structurally, 
FAK contains several distinct domains (Schaller, 2001).  It contains a central catalytic 
domain flanked by an amino-terminal FERM domain and a carboxy terminal proline-rich 
and FAK targeting domain (FAT) (Fig 1-2). The FERM domain is a key regulatory 
element as it interacts with several proteins including cytoplasmic tails of integrins 
(Calderwood et al., 1999), integrins associated proteins (Mitra and Schlaepfer, 2006) and 
epidermal growth factor receptor (EGFR) (Sieg et al., 2000). The FAT domain at the 
carboxy terminus is important in FAK localization by interacting with focal adhesion 
protein, paxillin (Hayashi et al., 2002), whereas the proline rich domains are involved in 
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binding with proteins containing SH3 domains including p130 Cas (Harte et al., 1996), 
GRAF (Taylor et al., 1998) and ASAP1 (Liu et al., 2002).  FAK is maintained in an 
inactive state by binding of its FERM domain to the kinase domain (Lietha et al., 2007). 
Integrin clustering leads to intracellular signals that relieve the autoinhibition, resulting in 
stimulation of FAK catalytic activity by autophosphorylation at tyrosine 397 (Y397). This 
auto-phosphorylation event creates a high-affinity binding site for the SH2 domain of Src 
family kinases and leading to the activation of Src (Schaller et al., 1994; Xing et al., 
1994). The activated Src in turn phosphorylates additional tyrosine residues on the kinase 
domain (Y576 and Y577) and carboxy-terminal domain (Y861 and Y925) of FAK. These 
phosphorylated residues form docking sites for other cytoplasmic proteins including p130 
Cas and paxillin (Schaller et al., 1999), p21-activated kinase and mitogen-activated 
protein kinase (MAPK) pathways and the small GTPases, Rac and Rho leading to the 
activation of various signaling cascades involved in migration and invasion (Schlaepfer 
and Mitra, 2004). In normal cells, FAK activity is under tight regulation by several 
mechanisms including gene amplification, alternative gene splicing (Toutant et al., 
2002)and action of phosphatases (Shen and Schaller, 1999). On the contrary, FAK levels 
are dramatically altered in a wide range of malignancies. The levels are increased in 
tumors of prostate (Tremblay et al., 1996), ovary (Judson et al., 1999), colon and breast 
(Cance et al., 2000). Increased FAK expression and activity is closely linked to 
metastasis and poor prognosis (Cance et al., 2000; Owens et al., 1995; Schlaepfer and 
Mitra, 2004). They are expressed at higher levels in invasive tumors as compared to 
benign preneoplastic lesions (Owens et al., 1995). 
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Figure 1-1: Organization of the domains of focal adhesion kinase (FAK) 
(Parsons, 2003) 
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 FAK deletion in a mouse skin tumorigenesis model has been shown to decrease 
papilloma formation and block progression to malignant squamous cell carcinoma 
(McLean et al., 2004). Phosphorylation of FAK at Y-397 residue has also been 
implicated in more aggressive tumors. In ovarian tissues, enhanced expression of 
phosphorylated FAK Y-397 was seen in invasive tumors as compared to the normal 
epithelium. The inhibition of FAK activity using a dominant negative form of FAK called 
FRNK (FAK related non-kinase) leads to the inhibition of cell migration, invasion and 
proliferation ((Hauck et al., 2002; Hauck et al., 2001; Slack et al., 2001). A study by Van 
de water (van Nimwegen et al., 2005) showed that inducible expression of FRNK in 
mammary adenocarcinoma cells suppressed tumor growth and lung metastasis 
significantly. Recently, a conditional knockout study of FAK deletion showed that 
abolishing FAK reduced Polyoma middle T oncoprotein (PyMT) induced breast 
tumorigenesis and reduced the ability of mammary tumor cells to invade and metastasize 
to lung (Pylayeva et al., 2009). Additionally, numerous studies using antisense and 
dominant negative mutants have strongly correlated the role of FAK in mediating cell 
migration and invasion of tumor cells. These data are summarized in Table 1- 1. 
FAK has also been implicated in deregulation of E-cadherin expression, a protein 
involved in epithelial mesenchymal transition (EMT). This is another prominent 
mechanism involved in tumor cell invasion. During this process epithelial cells lose the 
cell-cell contacts and epithelial markers like E-cadherin and γ-catenin and acquire 
fibroblast like phenotype and mesenchymal markers like fibronectin, vimentin, N-
cadherin. This switch from epithelial to mesenchymal phenotype is important for most  
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Table 1-1: Evidence showing correlation of FAK expression and activity in cell migration and 
invasion of tumor cells  
Modified from (Gabarra-Niecko et al., 2003) 
Cells FAK status Biological Effect Reference 
Melanoma 
Inhibit expression with 
antisense or FRNK 
Loss of cell adhesion 
(Maung et al., 
1999) 
Melanoma (highly 
metastatic) 
Inhibit signaling with 
FRNK 
Inhibit migration 
Inhibit invasion 
(Li et al., 2001c) 
Breast 
Inhibit expression with 
antisense 
Irreversible loss of adhesion 
(Xu et al., 2000; 
Xu et al., 1998) 
NSCLC 
Inhibit expression with 
antisense 
Decrease adhesion independent 
growth 
(Leyton et al., 
2001) 
Prostate carcinoma 
Inhibit signaling with 
FRNK 
Inhibit migration 
(Slack et al., 
2001) 
Ovarian cancer 
Inhibit expression with 
antisense 
Inhibit invasion 
(Shibata et al., 
1998) 
Adenocarcinoma 
Inhibit expression with 
antisense, no expression 
(FAK-/-), inhibit 
signaling with FRNK 
Inhibit EGF-mediated motility 
and invasion 
(Hauck et al., 
2001) 
Astrocytoma 
Increase expression by 
overexpression 
Increase migration 
(Zagzag et al., 
2000) 
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tumors to become invasive and aggressive (Kang and Massague, 2004). Some of the 
transcription factors mediating EMT and involved in metastatic dissemination are 
TWIST1 (Yang et al., 2004), Snail (Barrallo-Gimeno and Nieto, 2005) and Slug (Alves et 
al., 2009).  
Src family of Kinases (SFKs)  
The other family of non-receptor tyrosine kinases is the Src family of kinases. They are 
associated with FAK and integrins at focal contacts and play an important role in the 
integrin signaling. This family includes c-Src, Fyn, Yes, Blk, Lyn, Hck and Lck (Thomas 
and Brugge, 1997). c-Src is the most extensively studied member of this family and has 
been implicated in tumor progression (Irby and Yeatman, 2000). Discovered by Michael 
Bishop and Harold Varmus, c-Src is the first cellular homologue of the retroviral v-Src 
protein identified in the late 1970s by Francis Peyton Rous(Stehelin et al., 1977) . c-Src 
and v-Src share similar structures except for a truncation in the regulatory carboxy 
terminus which features loss of the auto-inhibitory tyrosine 527 residue (Takeya and 
Hanafusa, 1982) making v-Src constitutively active. Unlike v-Src, c-Src is non-
transforming in nature but once activated, can be converted to a transforming protein by 
various modifications including dephosphorylation of tyrosine-527 which is consistent 
with its role as a proto-oncogene (Der, 1987). Src protein is characterized by several 
distinct domains. It contains C-terminal domain containing a negative regulatory tyrosine 
residue (Tyr-527), four SH (Src homology) domains and a N-terminal domain which may 
undergo myristoylation (Engen et al., 2008). Src is present in an inactive state and 
inhibited state under normal conditions (Brown and Cooper, 1996). Binding of the of Src-
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SH2 domain to FAK brings about a conformational change in Src relieving the auto 
inhibition of Src kinase and  phosphorylation of the activating tyrosine residue (Tyr-416) 
on the first SH1 kinase domain of Src (Schlaepfer et al., 2004)  . The activated Src and 
FAK form a functional bipartite kinase complex leading to the activation of several 
downstream signaling cascades important in cell motility, adhesion and invasion (Mitra 
and Schlaepfer, 2006). FAK-Src signaling has been shown to be involved in activation of 
Rac1 activity (Brown et al., 2005; Ren et al., 2000), a member of the Rho family of 
GTPases involved in cytoskeletal remodeling (Raftopoulou and Hall, 2004). FAK-Src 
signaling has also been implicated in the transcriptional activation of MMP-2 and MMP-
9 (Hsia et al., 2003). Overexpression of c-Src and an increase in its catalytic activity has 
been implicated in various types of cancers (Irby and Yeatman, 2000) and increased c-Src 
kinase activity has been implicated with enhanced metastatic potential (Mao et al., 1997; 
Talamonti et al., 1993) through effects on motility and invasion (Jones et al., 2002). 
2. Survival in circulation-Anoikis Resistance 
Once tumor cells detach from the primary tumor mass, they enter into the 
circulatory or lymphatic system. This is called intravasastion. Once in the circulation, 
they no longer get the survival signals they normally receive from cell-cell and cell-ECM 
interactions. In normal epithelial cells the lack of cell-ECM interactions activates a 
special form of cell death called ‘anoikis’(Greek word for homelessness) (Frisch, 
2000).This is a safeguarding mechanism for normal cells to maintain tissue homeostasis 
and development and has significant physiological relevance. Various studies have 
focused on the importance of anoikis in the process of neoplastic transformation as seen 
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in malignant mammary (Streuli and Gilmore, 1999)and colon cancers (Shanmugathasan 
and Jothy, 2000). Tumor cells with metastatic potential acquire several mechanisms to 
evade this process and acquire resistance to anoikis which not only provides them with 
increased survival time but also facilitates reattachment and colonization at secondary 
sites. The molecular mechanisms involved in anoikis resistance are still not completely 
understood. Some of the prominent mechanisms include activation of survival pathways 
(PI3 kinase-AKT), upregulation of matrix metalloproteinases , inactivation of p53, 
overexpression of focal adhesion kinase (FAK) and anti-apoptotic proteins (BCL-2, 
BCL-XL,XIAP ) (Liotta and Kohn, 2004; Mehlen and Puisieux, 2006; Townson et al., 
2003).  A summary of the relevant pathways involved in anoikis resistance is shown in 
Table 1.2.  
3. Colonization and Growth at Distant Sites 
The last and final stage of the metastatic cascade is the colonization of the 
secondary site. Stephen Paget proposed a ‘seed and soil’ hypothesis according to which 
the disseminated tumor cells (seed) colonize to specific organs whose microenvironment 
(soil) is compatible for their growth and proliferation (Paget, 1889) For example, breast 
cancers frequently metastasize to lungs, liver, bone and brain whereas prostate cancers 
colonize to bone. This hypothesis was refuted by James Ewing who proposed that distant 
metastasis at specific sites is primarily determined by the vasculature at the primary site 
(Ewing, 1928). Recent advances and emerging data strongly support Paget’s hypothesis 
and stresses on the concept of viable tumor microenvironment or ‘premetastatic niche’ in  
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Mechanisms involved in 
anoikis resistance of  
tumor cells 
Activated pathways 
 References 
Constitutive activation of 
survival signals (PI3K, 
MEK/ERK, and NF-κB ) 
 
- Melanoma cells – Acquisition of autocrine loops 
for bFGF, HGF, PDGF-AA mediate 
proliferation,survival and migration. 
-Ovarian Cancer- upregulation of neurotrophin 
receptor,TrkB and subsequent activation of 
PI3K/Akt pathway lead to anoikis resistance 
 
(Nesbit et al., 
1999) 
(Li et al., 2003) 
(Douma et al., 
2004) 
Altered integrin mediated 
signaling 
1. Increased FAK activation 
2. Increased Src activation 
3. Changes in pattern of 
integrin expression 
 
1.Inhibition of FAK activity leads to anoikis in 
lung adenocrcinoma cells, A549 
2. Src activation mediates anoikis resistance in 
colon, Lung adenocarcinoma and osteosarcoma 
cells 
3.Melanoma cells: de novo expression of αvβ3 
integrin allows for survival within the dermis 
(Liu et al., 2008) 
(Windham et al., 
2002) 
(Montgomery et 
al., 1994) 
(Petitclerc et al., 
1999) 
Hypoxia 
 
- Hypoxia-driven N-cadherin expression promote 
anoikis resistance by induction of PKB/Akt 
activation and Bad inhibition 
- Hypoxia-induced ROS increase could be 
responsible for down-regulation of pro-apoptotic 
molecules 
(Li et al., 2001a) 
(Chandel et al., 
1998) 
Apoptosis regulators 
Activation of antiapoptotic members like Bcl2 
and XIAP implicated in promoting anoikis 
resistance 
(Berezovskaya et 
al., 2005; Galante 
et al., 2008) 
Epithelial mesenchyman 
transition (EMT) 
Twist, Snail, and NF-κB , transcription factors  
involved in the acquisition of anoikis resistance 
during the EMT process 
(Kucharczak et al., 
2003; Vega et al., 
2004; Yang et al., 
2004) 
 
 
Table 1-2: Mechanisms and pathways involved in anoikis resistance of tumor cells 
Modified from (Chiarugi and Giannoni, 2008) 
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grafting primary tumor cells to distant sites (Kaplan et al., 2006). Mobilization of bone 
marrow derived hematopoietic progenitor cells (HPCs) to the distant sites have been 
shown to be involved in metastatic initiation (Kaplan et al., 2005) by providing 
permissive tumor microenvironment at distant sites. These HPCs have been shown to 
express VEGFR1 and other progenitor markers like CD34, CD11b, c-kit, and Sca-1 and 
hence maintain their progenitor status at metastatic sites. Inhibition of VEGFR1 by 
neutralizing antibodies completely prevented metastasis. The bone marrow derived cells 
(BMDC) are tumor type specific as when LLC (Lewis Lung carcinoma cells are 
intradermally injected in animals, the BMDC cluster formation is seen specifically in 
lungs. VEGFR1+HPCs have been shown to express elevated levels of VLA-4 (α4β1) 
which binds to the newly synthesized fibronectin produced by fibroblasts in the tissue 
microenvironment. This allows the BMDC to adhere and form the premetastatic niche. 
Fibronectin interaction with VLA-4 also regulated the MMP-9 expression (Huhtala et al., 
1995). Upregulated MMP-9 expression degraded the basement membrane, and lead to the 
extravasation of more VEGFR1+ cells into the permissible niche. The VEGFR1+ HPCs, 
newly formed fibronectin and associated stromal cells alter the local microenvironment, 
leading to the activation of chemokines such as SDF-1 which attracts tumor cells 
expressing SDF-1 receptor CXCR4 as seen in previous studies (Balkwill, 2004; Muller et 
al., 2001) hence leading to enhanced attachment, survival, growth and retention of tumor 
cells at distant sites.  
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Section II: Apoptosis Regulators and Tumor Progression 
Aberrantly increased cell survival or resistance to death signals, as often observed 
in tumors, is an invariable requirement of metastasis (Mehlen and Puisieux, 2006). 
Apoptosis or programmed cell death is a tightly regulated cell suicide program required 
for normal cellular development and tissue homeostasis. Apoptosis is mediated by two 
distinct pathways called extrinsic and intrinsic pathways (Chen and Wang, 2002), both of 
which mediate apoptosis by forming multimeric complexes, which in turn activate 
several downstream caspases, key executioners of apoptosis (Bieberich et al., 2004; 
Cohen, 1997). Extrinsic (death receptor mediated) pathway is initiated by binding of 
ligands like TNF-α and Fas ligand (FasL) to their receptors TNFR and Fas (Krammer, 
2000) leading to activation of caspase 8, one of the initiator caspases. Intrinsic or 
mitochondria dependent pathway is activated by several intracellular signals like DNA 
damage, hypoxia and other intracellular cues. This leads to mitochondrial dysfunction 
(Wang, 2001) leading to release of cytochrome c and Smac. These mitochondrial changes 
lead to activation of caspase 9, an initiator caspase which then activates the downstream 
signaling cascade resulting in apoptosis.  
Defects in the regulation of apoptosis lead to malignant transformation. Indeed, 
the evasion of apoptosis has been listed as one of the six hallmarks of cancer (Hanahan 
and Weinberg, 2000). Since multiple mechanisms function at many levels to mediate 
apoptosis, a number of opportunities for apoptotic deregulation are available and can be 
exploited by the tumor cells. One of the several molecular mechanisms by which cancer 
cells are protected from apoptosis is through deregulated expression of protective 
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proteins like anti-apoptotic members of the Bcl-2 family or members of the inhibitor of 
apoptosis (IAP) family implicated in controlling mitochondrial integrity (Cory and 
Adams, 2002), or suppressing endogenous caspase activity (Eckelman et al., 2006), 
respectively. Apoptosis deregulation has also been implicated in drug resistance as 
various chemotherapeutic agents act via activation of apoptosis (Pommier et al., 2004). 
 Bcl2 family 
Bcl2 (B-cell lymphoma 2) family is comprised of both anti-apoptotic proteins that 
include that include Bcl-2, Bcl-XL, Bcl-w and pro-apoptotic members Bax, Bak, Bad, 
Bid, Bik.  All the members of this family are characterized by the presence of 1-4 copies 
of BH ( Bcl2 homology) domains (Figure1-2) and play an important role in the intrinsic 
pathway of apoptosis by regulating mitochondrial permeability (Cory and Adams, 2002). 
Bcl-2, the most well studied gene of this family, was discovered in follicular lymphoma 
where in Bcl2 was translocated into the immunoglobulin heavy chain locus resulting in 
upregulation of Bcl2 expression in B cells ((Tsujimoto et al., 1985).  
The oncogenic potential of Bcl2 has been demonstrated in various transgenic 
mouse models (Strasser et al., 1990; Vaux et al., 1988) and is primarily mediated by its 
ability to inhibit apoptosis without enhancing cell proliferation (Vaux et al., 1988). In 
fact, paradoxically, it has been shown to be anti proliferative and delays the G0 to S 
transition (Borner, 1996). The co-existence of contrasting anti apoptotic and anti-
proliferative functions of Bcl2 explains why Bcl2 induce tumors with low penetrance and 
require other genetic alterations like Myc for tumorigenesis (Fanidi et al., 1992; Strasser 
et al., 1990). Nevertheless, overexpression of Bcl2 has been detected in several human 
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cancers including breast (Leek et al., 1994), prostate (McDonnell et al., 1992) colon 
(Hague et al., 1994) and lung (Ikegaki et al., 1994). Stable expression of Bcl2 has been 
shown to induce  increased metastatic potential in pancreatic cell lines (Bold et al., 2001). 
However, most of the studies show that the effects of Bcl2 on tumor progression are 
primarily because of its antiapoptotic function which is mediated directly by controlling 
the activation of caspases (Adams and Cory, 1998) or indirectly by maintenance of the 
mitochondrial integrity (Green and Reed, 1998). The pancreatic cell line, Mia-Panc-1 
stably expressing Bcl2 is more resistant to apoptosis and forms larger primary tumors and 
higher number of liver metastasis (Bold et al., 2001). 
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Figure 1-2: Schematic representation of the Bcl2 family of proteins 
(Adams and Cory, 2001) 
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Inhibitor of Apoptosis (IAP) Family 
The inhibitor of apoptosis (IAP) gene was discovered 15 years back by Lois 
Miller and colleagues (Crook et al., 1993). This discovery led to the identification of 
cellular homologs in different species ranging from lower vertebrates to higher 
vertebrates . So far, eight members of this family have been identified in humans and are 
characterized by the presence of one or three baculovirus IAP repeat (BIR) protein 
domains of approximately 70 amino-acid residues (Hinds et al., 1999; Miller, 1999). 
Several IAPs also contain a CARD (caspase associated recruitment domain) and a RING 
domain (Joazeiro and Weissman, 2000) as shown in Figure 1.2. RING domains have 
been shown to function as E3 ubiquitin ligases. These RING domains work together with 
ubiquitin activating (E1) and conjugating (E2) enzymes to attach a ubiquitin moiety to 
the target proteins which then gets degraded by the proteasome (Jesenberger and Jentsch, 
2002; Yang et al., 2000). IAP proteins are involved in mediating various diverse and non 
redundant functions ranging from inhibition of apoptosis, to mitotic regulation. Caspase 
inhibition is one of the several mechanisms employed by IAPs like X-linked  
inhibitors of apoptosis (XIAP) to regulate apoptosis. They bind directly to caspase 3 and 
caspase 7 and inhibit their function. Several caspase independent mechanisms like NF-κB 
(Hofer-Warbinek et al., 2000) and Mitogen activated protein (MAP) kinase JNK1 (Sanna 
et al., 2002) activation have also been implicated in IAP mediated apoptotic inhibition. 
Although named for its role in apoptotic inhibition, IAPs have also been implicated in 
other diverse roles like copper homeostasis (Burstein et al., 2004), cell division 
(Srinivasula and Ashwell, 2008), ubiquitination (Park et al., 2008) and cell motility 
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(Geisbrecht and Montell, 2004). In this study, we have focused on survivin and XIAP, 
two of the more prominent members of this family that have gained much attention in the 
past several years.  
Structure and Functions of Survivin   
Survivin, a 16.5 kilodalton protein is a unique and smallest member of the IAP 
family (Salvesen and Duckett, 2002). It differs from the other members both structurally 
and functionally. It contains a single BIR domain (Refer to Figure 1.2), forms stable 
homodimers in solution (Verdecia et al., 2000), and its expression is regulated in a cell 
cycle dependent manner with a peak expression at the G2-M phase of the cell cycle (Li et 
al., 1998). Survivin is an oncofetal protein playing an important role in embryonic 
development. Survivin knockout mice die prematurely at embryonic day 3.5 with various 
mitotic and apoptotic defects suggesting an important role of survivin in mitotic 
regulation and apoptosis (Uren et al., 2000). However, its expression is undetectable in 
most adult cells and dramatically increased in virtually all human tumors tested 
suggesting an extremely important role played by survivin in tumorigenesis (Ambrosini 
et al., 1997) Survivin’s role in apoptotic inhibition has been characterized using both in 
vivo and in vitro models (Grossman et al., 2001; Kanwar et al., 2001; Olie et al., 2000). 
Increased expression of survivin has been shown to inhibit both the intrinsic and extrinsic 
apoptotic pathways and is primarily mediated by its interactions with other adaptor 
molecules and members of the apoptotic pathway through its N-terminal BIR domain 
(Ambrosini et al., 1997; Kobayashi et al., 1999; Mahotka et al., 1999). 
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Figure 1-3: Schematic representation of the Human IAP family of proteins 
(Srinivasula and Ashwell, 2008) 
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 Survivin, unlike other IAPs, does not bind with caspases directly (Eckelman et 
al., 2006). Instead, survivin uses alternate pathways such as forming a complex with 
hepatitis B-X-interacting protein (HBXIP) which inhibits caspase-9 leading to inhibition 
of mitochondrial apoptosis (Marusawa et al., 2003). Survivin also sequesters Smac, a 
proapoptotic mitochondrial protein released in the cytosol upon apoptotic induction and 
hence prevents association of Smac with other IAPs (Song et al., 2003). Also, survivin 
has been shown to delay the release of Smac/DIABLO from mitochondria when 
stimulated with DNA damaging agents like etoposide (Ceballos-Cancino et al., 2007). 
In addition to these mechanisms, under conditions of apoptotic induction, survivin 
physically interacts with X-linked inhibitor of apoptosis (XIAP), the only IAP member 
which directly interacts with caspase 3, 7 and 9.  This interaction leads to XIAP stability 
against ubiquitination and proteasomal degradation (Dohi et al., 2004). This study also 
showed a synergistic inhibition of apoptosis when stimulated HEK293 cells were 
transfected with survivin and XIAP together with Bax or Fas, activators of mitochondrial 
and death receptor pathways respectively. This intermolecular cooperation between IAPs 
is also seen between survivin and another IAP protein, BRUCE, which regulates 
cytokinesis (Pohl and Jentsch, 2008).  
IAP- IAP interactions are also important in regulating the activity and stability of 
IAPs. A study by Dohi et. al. (Dohi et al., 2007) has shown an important role of 
phosphorylation status in the regulation of survivin XIAP complex by using survivin 
mutants that lack (S20A) and mimic (S20E) sites phosphorylated by PKA. 
Phosphorylation of S20 residue of survivin (Ser20) by cyclic AMP dependent protein 
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kinase in cytosol (PKA) prevents binding of survivin to XIAP, hence inhibiting the 
cytoprotective function mediated by survivin and XIAP (Dohi et al., 2007). On the other 
hand, the mitochondrial survivin which is non-phosphorylatable by PKA binds to XIAP 
mediating its effects on cytoprotection by inhibition of caspase-9, XIAP stability and 
enhanced tumor growth (Dohi et al., 2007).  
In addition to its role in apoptosis inhibition, survivin plays an important role in 
mitosis by localizing to various components of the mitotic apparatus like centrosomes, 
microtubules and midbodies (Fortugno et al., 2002; Li et al., 1998). Physical associations 
of survivin with polymerized tubulin structures have been shown in vitro (Li et al., 1998). 
Survivin has also been shown to be a part of the chromosome passenger complex formed 
by Borealin, INCENP and Aurora B kinase (Adams et al., 2001). This complex is 
involved in proper chromosome segregation (Ruchaud et al., 2007) 
Because of its dual role in apoptosis inhibition and mitotic regulation, survivin 
has emerged as a valuable tool for therapeutic targeting as overexpression of survivin is 
observed in almost all tumor types tested and has surfaced as the fifth highly expressed 
transcript in cancer cells in human cancer transcriptome analysis (Velculescu et al., 
1999). It has been positively correlated to more aggressive tumors, poor prognosis, high 
tumor relapse rates and resistance to chemotherapy (Altieri, 2003). Numerous antagonists 
for targeting survivin are being tested and are summarized in Table 1-3.  
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Table 1-3: Survivin antagonists tested for targeted therapy 
(Altieri, 2008) 
 
 
Therapeutic approach Compounds Preclinical trials Clinical development
Antisense LY2181308 Completed
Phase I trial completed 
Phase II trial ongoing
Molecular antagonists Ribozyme RNA interference Ongoing Not started
Gene therapy
Dominant interfering mutants (C84A; 
T34A) Ongoing Not started
BIRC5 promoter for tumour-specific 
transcription of cytotoxic gene(s)‡ Ongoing Planned
Transcriptional repressors
EM-1421 (tetra-O -methyl 
nordihydroguaiaretic acid) Completed Phase I trial ongoing
YM155 Completed
Phase I trials completed 
Phase II trials ongoing
Small molecule antagonists of other 
pathways STAT3 (STA-21; WP1066) Completed Phase I trial planned
CDK1 (flavopiridol) Completed
Phase II trial ongoing 
(NCT00098371)
TCF (SDX-308) Completed Phase II trial ongoing
HSP90 (17-AAG) Completed
Phase I and II trials 
ongoing (NCT00096005, 
NCT00117988, 
NCT00096109)
ERBB2 (lapatinib or Tykerb) Completed
Phase III trials ongoing 
(NCT00374322)
Immunotherapy
Autologous CTL pulsed with survivin-
primed dendritic cells Completed
Phase I and II trials 
ongoing
Oral DNA vaccine (survivin peptide) Ongoing Planned
Peptidomimetic
Combined survivin and HSP90 antagonist 
(shepherdin) Ongoing Ongoing
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Structure and Functions of XIAP 
XIAP is one of the most extensively studied members of the IAP family. 
Structurally, XIAP contains three BIR domains, BIR-1, BIR-2 and BIR3 and a RING 
domain at the carboxy terminus as shown in Figure 1.2. The BIR-1 domain physically 
interacts with caspase 3 and caspase 7 (Eckelman et al., 2006) and BIR3 binds to  
caspase 9 (Shiozaki and Shi, 2004). The RING domain, an E3 ligase, mediates the 
process of ubiquitination leading to the degradation of target proteins including XIAP 
itself (Yang et al., 2000). Ubiquitination is an important regulatory step as mutants that 
lack the RING domain (RINGless) are relatively stable and resistant to apoptosis (Yang 
et al., 2000).  
XIAP regulation is also mediated by its interaction with Smac, a mitochondrial 
protein which is released into the cytosol when a cell undergoes apoptosis. Smac interacts 
with the BIR3 domain of XIAP, thus competing with the binding site of caspase-9 and 
releasing the XIAP inhibition of caspase-9 leading to apoptosis. Several peptides that 
mimic the XIAP binding site on Smac (referred as Smac mimmetics) have been shown to 
sensitize cells to apoptosis and are being clinically tested (Sun et al., 2008).  
Apart from its role as a caspase inhibitor, XIAP also functions as a cofactor in 
several pro survival pathways. XIAP has been shown to be involved in the activation of 
TGF-β signaling (Birkey Reffey et al., 2001), stress signaling pathways like N-terminal 
c-Jun kinase (JNK) pathway and the transcription factor NF-κB  (Hofer-Warbinek et al., 
2000). XIAP forms a complex with TAB1, a cofactor of TAB associated kinase (TAK1) 
and leads to JNK activation (Sanna et al., 2002) and NF-κΒ activation (Lu et al., 2007). 
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By virtue of its important role in apoptosis inhibition, XIAP has been closely 
correlated to tumorigenesis. Enhanced expression of XIAP is observed in various tumor 
cell lines (Yang et al., 2003). In addition, inhibition of XIAP has been demonstrated to 
sensitize tumor cells to chemotherapeutic agents (Bilim et al., 2003; McManus et al., 
2004; Sasaki et al., 2000). Elevated levels of XIAP have also been linked to poor 
prognosis in several tumors (Mizutani et al., 2007; Tamm et al., 2004). Additionally, 
XIAP expression has been linked with anoikis resistance in prostate tumor cells 
(Berezovskaya et al., 2005) and overexpressed in metastatic melanoma (Kluger et al., 
2007) pointing to an important role of XIAP in tumor progression. Thus XIAP qualifies 
itself as an important drug target for anticancer therapy. Several lead compounds and 
small molecule inhibitors are under clinical trials and are tested for different kind of 
tumors. The lists of all the XIAP antagonists are summarized in Table 1-4. 
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Table 1-4: Compounds targeted to different domains of XIAP 
Modified from (Schimmer et al., 2006) 
 
 
Therapeutic 
compound 
Developing organization Therapeutic 
Target 
Preclinical 
Stage 
 
Antisense 
AEG35136 
 
 
Aegera Therapeutics 
 
 
XIAP  mRNA 
 
Phase I 
Phase II 
Peptidomimetic 
Tripeptide 
Tripeptide 
 
Abbott Laboratories 
University of Michigan 
 
BIR3 
BIR3 
 
Preclinical 
Preclinical 
 
Natural Product  
Embeline 
 
University of Michigan 
 
BIR3 
 
Preclinical 
Synthetic 
Tetrazoyl thioether 
C2–symmetric diyne 
Aryl Sulfonamide 
Polyphenylurea 
 
University of Texas Southwest 
medical center 
Novartis 
Burnham institute/TPIMS 
 
BIR3 
BIR2 linker 
BIR2 
 
Preclinical 
Preclinical 
Preclinical 
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Section III: Role of NF-κΒ in tumor progression 
Deregulation of several signaling pathways has been implicated in tumor 
malignancies. Among them, one that is frequently altered in most human cancers is the 
IκB kinase (IKK)/nuclear factor (NF-κΒ) pathway (Basseres and Baldwin, 2006). In 
mammals, NF-κB family consists of five members- RelA (p65), RelB, c-Rel, NF-κB1 
(p50 and its precursor p105) and NF-κB2 (p52 and its precursor p100) (Ghosh et al., 
1998). These proteins exist both as homodimers and heterodimers and their activity is 
tightly regulated by a set of inhibitory IκB proteins (Hoffmann and Baltimore, 2006). 
 Under normal conditions, NF-κB is sequestered in the cytoplasm as an inactive, IκB-
bound complex. Upon stimulation by various agents like TNF-α, interleukins, genotoxic 
reagents, NF-κB rapidly enters the nucleus and activates gene expression of several target 
genes (Ghosh and Karin, 2002).  
Two pathways of NF-κB activation have been described (Hayden and Ghosh, 
2004). The classical pathway, wherein p65-p50 dimers are sequestered in cytosol 
together with Iκb-α under non-stimulated conditions (Li et al., 1999). On stimulation by 
various agents, the IκB- α is phosphorylated by IKK complex (serine specific IκB 
kinase) and hence ubiquitinated and degraded, thereby releasing the p65-p50 complex 
which then enter the nucleus and regulate gene expression. The alternate pathway 
involves the upstream kinase NF-κB inducing kinase (NIK) which on stimulation 
activates IKK complex which phosphorylates and degrades p100, the RelB inhibitor 
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releasing the RelB-p50 and RelB-p52 complex leading to nuclear translocation of these 
complexes (Solan et al., 2002).  
The key regulatory step for NF-κB activation is the IκB-NF-κB interaction. 
Tumor associated genetic alterations can disrupt the regulation of NF-κb and 
IκΒ proteins in turn causing constitutive activation of NF-κB. Constitutive activation of 
NF-κb family of transcription factors has been implicated in a wide variety of tumors of 
breast (Nakshatri et al., 1997; Sovak et al., 1997), pancreas (Wang et al., 1999b), liver 
(Qiao et al., 2006), prostate (Huang et al., 2001a), and several other cancers. It has been 
demonstrated to affect all six hallmarks of cancer through transcriptional activation of 
genes responsible for cell proliferation, suppression of apoptosis, angiogenesis, 
metastasis and inflammation (Basseres and Baldwin, 2006; Dutta et al., 2006; Jost and 
Ruland, 2007).  
Role of NF-κΒ in Tumor growth  
NF-κB mediates tumor growth and proliferation by the upregulation of several 
target genes involved in cell proliferation and cell cycle progression. One of the well 
studied targets of NF-κB mediated tumor cell survival is c-myc (Kim et al., 2000). 
Transcriptional activation of Pim-2, an oncogenic kinase involved in cell survival 
requires NF-κB activation (Fox et al., 2003). Similarly, NF-κB mediates the 
transcriptional activation of cyclin D1, a gene involved in G1 to S transition during cell 
cycle progression (Hinz et al., 1999). In addition to its role in upregulating genes 
involved in cell growth and proliferation, NF-κB also regulates the expression of several 
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antiapoptotic proteins like cIAPs (Wang et al., 2003), Bcl2 family members, survivin and 
XIAP (Karin and Lin, 2002). The property of NF-κB to inhibit apoptosis is primarily one 
of the main reasons behind resistance to chemotherapy observed in tumor cells with 
constitutively active NF-κB (Wang et al., 1999a).  
 
Role of NF-κΒ in tumor metastasis  
ΝF-κΒ has also been shown to play an important role in tumor metastasis by 
activating genes important at different steps of metastatic cascade. It upregulates genes 
that are important for tumor invasion, like matrix metalloproteinases, urokinase 
plasminogen activator (uPA) and interleukin-8 (IL-8). MMP-9 expression is 
transcriptionally regulated by NF-κΒ as it contains several -κΒ binding sites (Farina et 
al., 1999). NF-κΒ activation also plays an important role in mediating angiogenesis by 
upregulating the expression of several cytokines (like IL-8) and growth factors (e.g 
VEGF) (Chilov et al., 1997). Recent studies have shown the involvement of NF-
κΒ activation in mediating EMT (Huber et al., 2004). Repression of E-cadherin 
expression (Chua et al., 2007) and activation of Twist (Horikawa et al., 2007) by NF-
κΒ strengthens the involvement of NF-κΒ in mediating EMT. Additionally, NF-κb also 
activates genes which are important for homing of tumor cells to the distant sites like 
activation of a chemokine receptor, CXCR4 (Helbig et al., 2003)which is overexpressed 
in metastatic tumor cells and bind to its ligand, SDF-1 at distant sites leading to 
metastasis. (Muller et al., 2001)  
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Section IV: Concluding remarks 
It is clear that some of the well studied IAPs particularly survivin is upregulated 
in most invasive tumors and linked to poor prognosis, reduced survival rates and worse 
clinical outcome suggesting a strong link to tumor invasion and metastasis (Altieri, 
2003). However, the mechanistic link of IAPs to tumor metastasis is still not completely 
understood and we still lack a clear understanding of whether IAPs contributes to 
metastasis through their ability to block apoptosis or several additional mechanisms exist 
that contributes to tumor progression.  
In this study, we have focused our efforts in understanding two key questions. 
Firstly, can the IAPs particularly survivin act as metastasis gene in vitro and in vivo and 
what are the essential mechanistic requirements of IAP mediated tumor invasion and 
metastasis. And secondly, is the metastatic role of IAPs dependent or independent of their 
known antiapoptotic function (s)? We hypothesized that IAPs play a very different role in 
metastasis by upregulating a broad gene expression program. This is independent of their 
anti-apoptotic function and requires a synergistic co-operation of survivin with XIAP, 
two prominent IAP members, leading to the activation of NFκB in turn activating several 
genes leading to enhanced metastatic dissemination. 
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Chapter 2: Characterization of IAP-mediated tumor invasion in vitro 
 
Introduction 
Tumor metastasis is the deadliest aspect of cancer as it leads to the majority of all 
cancer deaths. Several gene alterations are responsible for converting a localized tumor to 
a more metastatic one. Gene expression profiling is one possible way to identify patients 
who are likely to develop metastatic cancer during the course of the disease (Fingleton, 
2007). Several studies have successfully identified gene targets that contribute positively 
to this conversion. One  such study carried by Todd Golub and his group  (Ramaswamy 
et al., 2003) identified  a gene expression signature (128 genes) that discriminated 
primary and metastatic adenocarcinomas. They showed that solid tumors carrying this 
signature are more likely to develop metastasis and show worse clinical outcome 
(Ramaswamy et al., 2003) Among other genes identified in this screen, survivin was 
identified as one of them. Survivin, a member of IAP family with known functions in 
apoptosis and mitosis, has been correlated with poor prognosis, reduced survival rates 
and worse clinical outcome (Altieri, 2003). Survivin has been closely linked to more 
invasive and aggressive tumors as enhanced expression of survivin is observed in more 
metastatic phenotypes in hepatocellular carcinomas (Zhu et al., 2005) ,ovarian (Yoshida 
et al., 2001), colon (Agui et al., 2002) and esophageal (Kato et al., 2001) cancers. 
Additionally, a study by Grossman et. al. (Thomas et al., 2007) showed that transgenic 
expression of survivin in melanocytes is associated with increased UV induced tumor 
growth and metastasis in vivo suggesting an important role of survivin at both early and 
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late stages of tumor progression. The mechanistic role of survivin in the process of tumor 
metastasis is not completely understood although apoptotic inhibition is considered to be 
one of the mechanisms involved in mediating metastasis (Mehlen and Puisieux, 2006). It 
is possible that several additional mechanisms are involved in survivin mediated 
metastasis as a study by Salz et. al. (Salz et al., 2005) showed that transgenic mice 
overexpressing survivin in the bladders is associated with upregulation of several cell 
adhesion molecules, including fibronectin.  
In this part of the study, using various different approaches, we provide evidence 
that survivin is a ‘metastasis gene’ which, together with XIAP, plays an important role in 
tumor migration and invasion via upregulation of gene expression most notably 
fibronectin. Using cell lines stably expressing IAPs we have dissected the cellular and 
signaling requirements of IAP mediated tumor cell invasion. 
Results  
IAP-mediated tumor cell invasion 
To study how IAPs may contribute to tumor progression, we stably transfected 
breast adenocarcinoma MCF-7 cells with a survivin (SVV) cDNA, and selected clones 
(MCF-7 SVV) expressing 2- to 3-fold increased survivin levels, as compared with 
parental cultures (Figure 2-1A). Although survivin is an essential mitotic gene, its 
expression in MCF-7 SVV cells did not affect cell proliferation (Figure 2-1B). 
Conversely, when added to collagen-coated inserts, MCF-7 SVV cells showed increased 
cell migration, compared to parental cells (Figure 2-1C). This response could not be 
attributed to differential adhesion to fibronectin- or collagen-containing substrates 
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(Figure 2-1D), or changes in actin cytoskeleton (Figure 2-1E), which were 
indistinguishable in MCF-7 and MCF-7 SVV cells.  In addition, and consistent with 
enhanced cell migration, MCF-7 SVV cells showed dramatically increased invasion 
across Matrigel-coated inserts, whereas non transfected MCF-7 cells or MCF-7 cells 
transfected with empty plasmid were not invasive (Figure 2-1F). In order to test if the 
dramatic invasiveness seen in stably expressing MCF-7 cells is not arising due to clonal 
selection process, we tested another independent clone of MCF-7-SVV and both the 
clones showed similar results (Figure 2-1F).   
To test whether IAPs participated in this response, we next silenced survivin or 
XIAP expression in MCF-7 SVV cells by small interfering RNA (siRNA). Survivin- or 
XIAP-directed siRNA efficiently reduced the expression of the intended target protein, 
but not vice versa, and a non-targeted siRNA was ineffective (Figure 2-2A). Under these 
conditions, knockdown of survivin or XIAP nearly abolished MCF-7 SVV cell invasion 
through Matrigel inserts, as compared with control transfectants (Figure 2-2B). Within 
the same time frame of the invasion assay, survivin or XIAP knockdown caused only a 
modest decrease in MCF-7 SVV cell viability (7% and 14.2%, respectively), compared to 
control transfectants (4.8%) (data not shown). In parallel, we targeted survivin function 
using a survivin Cys84→Ala/Thr34→Ala double mutant (pAd-T34AC84A). This mutant 
is unstable in vivo, homodimerizes with the endogenous protein and promotes accelerated 
degradation of the complex (not shown), i.e. it is a dominant negative. MCF-7 SVV cells 
transduced with adenovirus pAd-GFP or pAd-T34AC84A, expressed comparable levels 
of GFP, by fluorescence microscopy (Figure 2-2C). In contrast, expression of pAd-
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T34AC84A, but not control virus, suppressed MCF-7 SVV cell invasion through 
Matrigel inserts (Figure 2-2D).  Similar to the knockdown results, cells transfected with 
pAd-T34AC84A showed no changes in cell proliferation or cell survival within the time 
interval of the invasion assay (Figure 2-2E). 
To test whether this response was unique to MCF-7 cells, we then targeted IAPs 
in different, unrelated tumor cell types. siRNA knockdown of XIAP or survivin in breast 
adenocarcinoma MDA-MB-231 (Figure 2-3A), or prostate adenocarcinoma cells, PC3 
(Figure 2-3C) also abolished their invasion through Matrigel inserts, compared to non-
targeted transfectants (Figure 2-3B, D).   
To further establish a role of IAPs in tumor cell invasion, we then looked at 
isogenic tumor cell types carrying homozygous deletion of XIAP. Wild type (XIAP+/+) 
colorectal adenocarcinoma HCT116 cells efficiently invaded through Matrigel inserts, 
whereas XIAP-/- cells had no invasive potential in this assay (Figure 2-4A). Additionally, 
we also generated MCF-SVV cell line containing stable knockdown of XIAP. We tested 
the knockdown efficiency by western blotting (Figure 2-4B). Stable knockdown of XIAP 
abolished the ability of these cells to invade suggesting an important role of XIAP in 
tumor invasion (Figure 2-4B).  
IAP anti-apoptotic function(s) are not required for tumor cell invasion 
 To test whether the ability of IAPs to inhibit cell death contributed to tumor cell 
invasion, we next used a model of rat insulinoma INS-1 cells (Figure 2-5A).  Previous 
studies from our lab showed that stable transfection of survivin in these cells (INS-1 
SVV) does not inhibit apoptosis, due to defective mitochondrial import (Dohi et al., 
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2007).  Regardless, INS-1 SVV cells readily invaded through Matrigel inserts, whereas 
control INS-1 transfectants were not invasive in this assay (Figure 2-5B).  In addition, 
stable transfection of anti-apoptotic Bcl-2 in INS-1 cells (Figure 2-5A), which promoted 
exponential tumor growth in vivo, thus confirming its activity (Dohi et al., 2007), did not 
significantly mediate tumor cell invasion (Figure 2-5B).  We next asked whether a similar 
paradigm applied to XIAP, and we stably transfected XIAP-/- HCT116 cells with a XIAP 
Asp143Ala/Trp310Ala double mutant (D143A/W310A) that does not bind caspase 3 
(D143A mutation), nor caspase 9 (W310A mutation), and is thus devoid of anti-apoptotic 
functions (Lewis et al., 2004) (Figure 2-5C).  Independent clones of this cell line robustly 
invaded through Matrigel inserts, quantitatively indistinguishably from XIAP-/- cells 
reconstituted with wild type, i.e. anti-apoptotic, XIAP (Figure 2-5D). 
IAP induction of fibronectin regulates tumor cell invasion  
 To begin understanding how IAPs promote tumor cell invasion, we next looked 
at the gene expression profile of model MCF-7 SVV cells, in which expression of 
survivin, alone, was sufficient to confer a highly invasive phenotype (Figure 2-1F).  
Microarray analysis of these cells revealed a significant upregulation of multiple 
extracellular matrix proteins implicated in cell invasion, including lumican (↑4106-fold), 
fibronectin (↑334-fold), and laminin α4 (↑105-fold) (Table 2-1).  Accordingly, MCF-7 
SVV cells exhibited a >120-fold upregulation of fibronectin mRNA, by real-time PCR 
(Figure 2-6A), and increased fibronectin promoter activity, by luciferase reporter assay  
(Figure 2-6B), compared to non-transfected MCF-7 cells.  Collagen type 1 α1 and 
collagen type 5 α2 mRNAs were also increased in MCF-7 SVV cells, albeit less 
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prominently, whereas expression of laminin 5 was not significantly different, compared 
to parental cultures (Figure 2-6A).  Consistent with these data, MCF-7 SVV cells 
exhibited a dramatic increase in endogenous fibronectin protein content, by fluorescence 
microscopy (Figure 2-6C), and Western blotting (Figure 2-6D).  In addition, the newly 
produced fibronectin was readily released pericellularly in the conditioned medium of 
MCF-7 SVV cells (Figure 2-6E).  This was functionally important because MCF-7 SVV 
cells showed robust migration on Transwell inserts even in the absence of exogenously 
added substrate (Figure 2-6F), indicating that fibronectin produced and released under 
these conditions conferred a general migratory phenotype, independent of substrate.  In 
contrast, parental MCF-7 cells did not migrate in the absence of substrate (Figure 2-6F).  
Similar results were obtained with an unrelated cell type, as INS-1 cells stably transfected 
with survivin (INS-1 SVV) also exhibited a 7- to 8-fold increased fibronectin mRNA, by 
PCR amplification (Figure 2-7A), and fibronectin protein, by Western blotting  
(Figure 2-7B).  In contrast, INS-1 Bcl-2 transfectants, or cells transfected with a control 
plasmid, showed no modulation of fibronectin levels (Figure 2-7 A, B). 
Using breast cancer as a model, we next asked whether a relationship between 
IAP and fibronectin expression existed in human tumors, in vivo.  Analysis of two 
independent published gene profiling studies revealed that survivin and fibronectin were 
coordinately increased in tumor versus normal tissues (Figure 2-8A, B).  This likely 
reflected expression of fibronectin in the tumor cell population, rather than stromal cells, 
because additional invasive breast adenocarcinoma cell types, including SUM159 and 
HBL100 cells, also contained higher levels of endogenous fibronectin (Figure 2-8C). 
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To begin investigating whether increased production of fibronectin contributed to 
tumor cell invasion, we employed two approaches, siRNA silencing of fibronectin and 
antibody blockade experiments. Acute siRNA knockdown of fibronectin in MCF-7 SVV 
cells (Figure 2-9A) significantly inhibited matrigel invasion by approximately 50%  
(Figure 2-9B). As a second approach, pre-incubation of MCF-7 SVV with a function 
blocking antibody to β1 integrin (s) which comprises the main cellular fibronectin 
receptor on these cells, abolished tumor cells invasion, as compared with non-binding 
IgG (Figure 2-9 C). These data suggest that β1 integrin recognition of fibronectin, and 
potentially additional adhesive ligands transcriptionally upregulated in IAP-expressing 
cells, mediates tumor cell invasion. Conversely, no quantitative changes were observed in 
overall integrin expression in MCF-7 and MCF-7 SVV cells (Figure 2-10).   
Signaling requirements of IAP-mediated tumor cell invasion 
 To identify downstream signals of IAP-mediated tumor cell invasion, we next 
focused on kinase cascades implicated in cell motility. Under attached conditions, MCF-7 
SVV cells exhibited a constitutively higher level of phosphorylated FAK (Tyr397) 
(Figure 2-11A), and Src (Tyr416) (Figure 2-11B), compared to parental MCF-7 cells. In 
contrast, phosphorylated Akt (Figure 2-11C), or ERK1, 2 (Figure 2-11D) was comparable 
in the two cell types, and total protein content of the various kinases was unchanged 
(Figure 2-11A-D). We next used the model of transfected INS-1 cells to check the 
requirement of IAPs in the constitutive activation of these kinases. Compared to control 
cultures, INS-1 cells expressing wild type survivin exhibited constitutively elevated 
levels of phosphorylated Src (Figure 2-11E). In contrast, two independent clones of  
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INS-1 cells transfected with a survivin S20E mutant that does not bind XIAP had no 
detectable phosphorylated Src (Figure2-11E). This strongly suggests that survivin-XIAP 
complex is indeed essential for the upregulation of phospho-Src mediated cell signaling.  
Functionally, targeting FAK by expressing a dominant negative truncated FAK 
mutant, FRNK (Figure 2-12A), inhibited MCF-7 SVV cell invasion, compared to control 
transfectants (Figure 2-12B). Similarly, two pharmacologic inhibitors of Src, PP2  
(Figure 2-11C) or SU6656 (Figure 2-12D), abolished Matrigel invasion of MCF-7 SVV  
whereas pharmacologic antagonists of MEK (PD98059 or U0126), or PI3 kinase 
(LY294002) had no effect (Figure 2-12C). All the pharmacologic inhibitors tested 
suppressed phosphorylation of the intended target kinases, validating their specificity 
(Figure2-12E-G). As control, Src antagonists did not affect cell viability or cell cycle 
kinetics of MCF-7 SVV cultures (Figure 2-13). The suppression of invasion by PP2 was 
also seen in another invasive breast cancer line, MDA-MB-231 cells (Figure 2-14).  
IAP protection from anoikis  
The ability of tumor cells to remain viable when detached from the extracellular 
matrix, i.e. anoikis, may contribute to metastasis, and a role of the IAP pathway in this 
response was next investigated.  MCF-7 cells maintained in suspension using ultra-low 
(U-L) attachment plates showed time-dependent anoikis-associated apoptosis (Frisch and 
Screaton, 2001), as determined by hypodiploid DNA content (Figure 2-15A), and 
increased released of apoptogenic Smac from mitochondria (Figure 2-15B).  In contrast, 
MCF-7 SVV cells were completely protected from anoikis-induced cell death  
(Figure 2-15A), and exhibited reduced release of Smac from mitochondria  
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(Figure 2-15B).  When attached to substrate, there was no difference in background 
levels of Smac release between MCF-7 and MCF-7 SVV cells (Figure 2-15B).  siRNA 
knockdown of survivin in MCF-7 SVV cells in suspension (Figure 2-15C) reversed 
cytoprotection against anoikis, and strongly enhanced cell death under these conditions 
(Figure 2-15D).  Conversely, survivin silencing in attached MCF-7 SVV cells  
(Figure 2-15C) did not significantly reduce cell viability within the same time interval 
(Figure 2-15D). 
Although survivin is required to counter anoikis (Figure 2-15D), MCF-7 SVV 
cells in suspension did not reveal redistribution of survivin from its mitochondrial stores 
to the cytosol (Figure 2-16A), which is required for apoptosis inhibition (Dohi et al., 
2007).  Instead, MCF-7 SVV cells in suspension exhibited constitutive phosphorylation 
of FAK and Src (Figure 2-16B), a mechanism previously implicated in protection from 
anoikis (Bouchard et al., 2008).  In contrast, parental MCF-7 cells did not phosphorylate 
these kinases in suspension, and total FAK and Src protein content was comparable in 
both cell types (Figure 2-16B).  Confirming the mechanistic requirements of this 
response, siRNA knockdown of fibronectin (Figure 2-17A), or its receptor, β1 integrin(s) 
(Figure 2-17B), suppressed FAK and Src phosphorylation in MCF-7 SVV cells 
maintained suspension.  Therefore, similarly to the requirements of tumor cell invasion, 
IAP suppression of anoikis involves constitutive phosphorylation of FAK and Src via 
fibronectin-β1 integrin signaling, and this response is independent of tumor cell 
attachment to substrate. 
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Discussion 
Although well recognized for their role in cytoprotection, IAPs are now viewed as 
more general regulators of cellular homeostasis (Srinivasula and Ashwell, 2008). In this 
context, their role in cell motility may be evolutionary conserved, as a Drosophila IAP 
homolog has been implicated in cytoskeletal rearrangement and cell migration 
(Geisbrecht and Montell, 2004), via activation of small GTPase signaling (Oshima et al., 
2006). However, whether a similar model applied to mammalian cells has remained 
unclear, as recent findings suggested that loss of IAPs, including XIAP, resulted in 
increased cell motility, potentially via enhanced stability of the c-Raf  kinase (Dogan et 
al., 2008). At variance with these data, we have shown here that IAP signaling is 
sufficient to convert poorly migratory and non-invasive breast adenocarcinoma MCF-7 
cells into a highly mobile and invasive cell type, competent to support extensive 
metastatic dissemination, in vivo. Although it remains possible that this discrepancy may 
be explained by a different utilization of c-Raf for cell motility (Dogan et al., 2008), 
rather than cell invasion, which is the process investigated here, it should also be noted 
that previous studies demonstrated that activated c-Raf (i.e. Raf-1) has a profound 
inhibitory effect on cell migration (Slack et al., 1999), potentially via inhibition of 
integrin activation (Hughes et al., 1997), which is required for the pathway of tumor cell 
invasion described here. Accordingly, evidence obtained here from compounded gene 
silencing strategies, dominant negative interference, and analysis of IAP knockout cells, 
in vitro and in vivo, points to IAP-dependent tumor cell invasion as a general property of 
disparate cancer types, regardless of genetic makeup or tissue of origin. 
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One of the pivotal requirements of this pathway was a dramatic upregulation of 
fibronectin in tumor cells, which involved de novo transcription of a proximal, 1.9 kb 
region of the fibronectin gene, and release of newly produced fibronectin protein in the 
extracellular environment. Overall, this model fits well with the observation that 
fibronectin is often over-expressed in cancer (Bittner et al., 2000), directly enhancing the 
metastatic phenotype of tumor cells (Clark et al., 2000), and contributing to the 
composition of a metastatic niche in the tumor microenvironment (Kaplan et al., 2005). 
With respect to breast cancer, i.e. a disease model used here, high fibronectin levels have 
been associated with loss of epithelial polarity (Nelson and Bissell, 2006), increased 
tissue rigidity (Paszek et al., 2005), resistance to hormonal therapy (Helleman et al., 
2008), and disruption of mammary acinar morphogenesis (Williams et al., 2008).  There 
is also evidence that fibronectin-initiated signaling may dictate negative disease outcome, 
as elevated levels of fibronectin, or its main cellular receptor, β1 integrin(s), have been 
linked to shortened overall and disease-free survival in breast cancer patients (Yao et al., 
2007), as well as high rates of recurrences and distant metastasis in patients with bladder 
cancer (Dyrskjot et al., 2003).  In this context, deregulated IAP expression has been 
linked to high levels of fibronectin in a transgenic mouse model of bladder cancer (Salz 
et al., 2005), and in retrospective analysis of breast cancer patients, in vivo (this study). In 
addition, the fact that several, unrelated tumor cell types exhibited constitutively high 
levels of fibronectin suggests that its expression in microarray analysis of primary tumor 
specimens reflects a property of the tumor cell population, rather than a differential 
composition of tumor-associated stroma. 
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How does fibronectin increase in IAP-expressing cells mediate tumor cell 
invasion? Data obtained here using function-blocking antibodies, siRNA silencing, and 
molecular or pharmacologic targeting of signaling kinases suggest a paracrine model, in 
which fibronectin released from the tumor cells engages β1 integrins at the cell surface, 
culminating with constitutively high levels of phosphorylated, i.e. activated FAK and Src, 
required for cell invasion. This is consistent with current paradigms of outside-in 
signaling by integrins, including β1 integrins (Ginsberg et al., 2005), and their ability to 
trigger activating phosphorylation of Src (Mitra and Schlaepfer, 2006), and FAK (Sieg et 
al., 2000), thus conferring invasive potential to disparate cell types, in vivo (Parsons et al., 
2008). Although it is plausible that additional mechanism(s) (Bialek et al., 2004) may 
contribute to FAK/Src activation under these conditions, including a potential modulation 
of growth factor receptor signaling, disruption of a survivin-XIAP complex using a 
phosphorylation-mimetic survivin S20E mutant (Dohi et al., 2007) strongly reduced Src 
phosphorylation in IAP-expressing cells.  Importantly, this pathway was operational in 
cells maintained in suspension, thus bypassing the requirement of cell adhesion to 
extracellular matrix substrates for kinase activation. Under these conditions, IAP-
expressing cells forced to remain in suspension were completely protected against 
anoikis-associated cell death, and this pathway required their expression of survivin.  
However, suppression of anoikis under these conditions did not result from release of 
survivin from its mitochondrial, i.e. cytoprotective, stores (Dohi et al., 2007), suggesting 
that fibronectin-mediated paracrine activation of FAK/Src was sufficient to counter 
43 
anoikis (Frisch and Screaton, 2001), and preserve mitochondrial integrity, potentially via 
PI3 kinase/Akt modulation of Bcl-2 family proteins (Bouchard et al., 2008). 
To summarize this part of the study, we have demonstrated that survivin and 
XIAP both play an important role in tumor invasion in vitro. This is well supported by in 
vivo data described in Chapter 4. Survivin mediated tumor invasion requires activation of 
a broad gene expression program, leading to activation of various cell adhesion 
molecules particularly fibronectin. Fibronectin in turn bind to integrin receptors leading 
to the activation of cell motility kinases, FAK and Src which gets activated leading to 
enhanced tumor invasion. 
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Figure 2-1: Characterization of MCF-7 cells stably expressing survivin  
A) Extracts (20-80 ug) from MCF-7 or MCF-7 cells stably transfected with survivin (MCF-7 SVV) were 
analyzed by Western blotting.  (B) MCF-7 or MCF-7 SVV cells were analyzed at the indicated time 
intervals, by MTT.  (C) MCF-7 or MCF-7 SVV cells were added to collagen-coated transwell inserts, and 
migrated cells were visualized after 1 h by DAPI staining (left), and quantified (right).  (D) MCF-7 or 
MCF-7 SVV cells were added to fibronectin (Fn)- or collagen (Col)-coated plates, and cell adhesion was 
quantified after 1 h.  (E) MCF-7 or MCF-7 SVV cells adherent to fibronectin (Fn) - or collagen (Col)-
coated plates were stained with FITC-conjugated phalloidin, and imaged by fluorescence microscopy.  (F) 
MCF-7, two clones of MCF-7 transfected with empty vector or two independently established clones of 
MCF-7 SVV cells (#1 and #2) were added to Matrigel-coated Transwell inserts, and invaded cells were 
visualized after 6 h by DAPI staining (left), and quantified (right). For panels C and F, data are the 
mean±SD of two transwells of a representative experiment out of at least two independent determinations. 
** p=0.0081, ** p=0.0091, * p=0.12, *p=0.0062 
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Figure 2-2: IAP-regulation of tumor cell invasion 
A) MCF-7 SVV cells were transfected with control (Ctrl) or survivin (SVV) - or XIAP-directed siRNA, 
and analyzed by Western blotting. (B) siRNA transfected MCF-7 SVV cells that invaded through Matrigel-
coated inserts were visualized by DAPI staining after 6 h (left), and quantified (right). (C) MCF-7 SVV 
cells were transduced with pAd-GFP or survivin pAd-T34AC84A double dominant negative mutant, and 
imaged for GFP expression after 24 h, by fluorescence microscopy.  (D) Transduced MCF-7 SVV cells 
were analyzed for Matrigel invasion after 6 h by DAPI staining (left), and quantified (right).  (E) Untreated 
or transduced MCF-7 SVV cells were analyzed after 24 h for DNA content by propidium iodide staining 
and flow cytometry. The percentage of cells in G1 and G2/M transitions is indicated. For panels B and D, 
data are the mean±SD of duplicates of a representative experiment out of at least two independent 
determinations. 
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Figure 2-3: IAP-dependent tumor cell invasion  
(A, C) Breast adenocarcinoma MDA-MB-231 (A) or prostate adenocarcinoma PC3 (C) cells were 
transfected with control (Ctrl) or survivin (SVV) - or XIAP-directed siRNA, and analyzed by Western 
blotting after 48 h.  *non-specific. (B, D) Transfected MDA-MB-231 (B) or PC3 (D) cells were analyzed 
for invasion through Matrigel-coated Transwell inserts by DAPI staining (center), and quantified (right).   
Data in panels B and D are mean±S.D of two transwells of a representative experiment out of at least two 
independent determinations.  
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Figure 2-4: XIAP-regulation of tumor cell invasion  
(A) Wild type or XIAP-/- HCT116 cells were analyzed for XIAP and survivin levels by immunoblotting. 
(left panel, cells were analysed for matrigel invasion after 6 h by DAPI staining (middle panel), and 
quantified (right panel) (B) MCF-7 SVV cells stably tranduced with two independent shRNA clones of 
XIAP (#1 and # 2) were analyzed by western blotting for XIAP and 14-3-3β (left panel) and analyzed for 
Matrigel invasion after 6 h (right panel).  
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Figure 2-5:  IAP mediated tumor invasion independent of its anti-apoptotic function(s).  
(A) Rat insulinoma INS-1 cells stably transfected with pcDNA, survivin (SVV) or Bcl2 were analyzed by 
Western blotting. (B) Stable INS-1 transfectants were quantified for matrigel invasion after 48hrs.  
(C) XIAP-/- HCT116 cells were stably transfected with WT XIAP or XIAP D143A/W310A mutant, and 
analyzed by Western blotting.  Wild type (XIAP+/+) HCT116 cells were used as a control *, non-specific 
 (D) XIAP-/- HCT116 cells stably expressing WT XIAP or XIAP D143A/W310A mutant (clones #123 and 
#126) were quantified for Matrigel invasion after 6 h by DAPI staining. 
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Table 2-1:  Microarray analysis of MCF-7 and MCF-7 SVV cells 
  Fold Change Gene ID Gene Name 
1 Up 4106.7 NM_002345 Lumican 
2 Up 334 BC005858 Fibronectin 1 
3 Down 302.33 NM_000115 Endothelin receptor type B 
4 Up 119 AI123532 Neuronal growth regulator 1 
5 Up 105.57 NM_002290 Laminin, alpha 4 
6 Up 88.38 AI817041 Chemokine (C-X-C motif) receptor 7 
7 Down 85.72 NM_000523 Homeobox D13 
8 Down 69.95 AA845258 Biglycan 
9 Up 64.58 M21121 Chemokine (C-C motif) ligand 5 
10 Up 63.5 NM_016644 Proline rich 16 
11 Up 62 BC042995 
CKLF-like MARVEL  
transmembrane domain 
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Figure 2-6: IAP mediated induction of fibronectin gene expression  
A)  RNA from MCF-7 or MCF-7 SVV cells was amplified for the indicated gene products, and normalized 
to GAPDH expression.  Fn, fibronectin; Lam 5, laminin 5; CollA1, collagen A1; Coll VA2, collagen V A2.  
(B) MCF-7 or MCF-7 SVV cells transfected with pcDNA or a fibronectin luciferase promoter construct 
(pGL-Fib) were analyzed after 24 h for β-galactosidase-normalized luciferase activity.  RLU, relative 
luciferase units. (C) MCF-7 or MCF-7 SVV cells were stained with an antibody to fibronectin (red), and 
imaged by fluorescence microscopy, DNA was stained with DAPI (blue). (D)  MCF-7 or MCF-7 SVV cells 
were analyzed by Western blotting. (E) Aliquots of conditioned media isolated from comparable numbers 
of MCF-7 or MCF-7 SVV cells were analyzed after 48 h by Western blotting. (F) Cell migration on 
uncoated transwell inserts was analyzed by DAPI staining (left), and quantified (right). 
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 Figure 2-7: IAP regulation of fibronectin in INS-1 cells.  
 (A) Total RNA extracted from Rat insulinoma INS-1transfectants was amplified with primers for 
fibronectin, and normalized for GAPDH levels.  (B) Parental INS-1 cells or INS-1 stably transfected as 
indicated were analyzed by Western blotting.  Fn, fibronectin.  
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Figure 2-8: Correlative evidence of Tumor-associated fibronectin and survivin expression by 
microarray analysis 
(A, B) Analysis of two published data sets (Richardson et al., 2006) (Turashvili et al., 2007) were analyzed 
for the expression of survivin and fibronectin in tumor (T) versus normal (N) tissues.  
(C) The indicated breast (HBL100, SUM159) or prostate (PC3) tumor cell types were analyzed by Western 
blotting to see the tumor-associated endogenous fibronectin expression. 
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Figure 2-9: Fibronectin regulation of tumor cell invasion   
(A) MCF-7 SVV cells were transfected with control (Ctrl) or fibronectin (Fn)-directed siRNA, and 
analyzed by Western blotting after 48 h.  (B) siRNA transfected MCF-7 SVV cells were analyzed for 
Matrigel invasion after 6 h by DAPI staining (left), and quantified (right). (C) MCF-7 SVV cells were 
incubated with a function-blocking antibody to β1 integrin (β1), or IgG, and DAPI stained (left) and 
quantified for Matrigel invasion after 6 h (right). For panels A and C, data are mean± SD of two transwells 
of a representative experiment out of at least two independent determinations. ***, p=0.0006 
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Figure 2-10 : Surface staining of integrins in MCF-7 and MCF-7 SVV   
MCF-7 and MCF-7 SVV cells were stained for surface receptors β1, β4, β6, αv and α6 and analyzed by 
flowcytometry.   
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Figure 2-11: Signaling requirements of IAP-dependent tumor cell invasion  
A) Adherent MCF-7 SVV cells were analyzed after 48 h by Western blotting for phosphorylation/ 
expression of FAK (A), Src (B), Akt (C), or ERK1, 2 (D).  (E) INS-1 cells stably transfected with wild type 
survivin (SVV) or two independent clones of survivin S20E mutant (#2 and #6) were analyzed by Western 
blotting.   
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Figure 2-12: FAK/Src-regulation of IAP-mediated tumor cell invasion  
MCF-7 SVV cells were transfected with pcDNA or FRNK cDNA, and analyzed after 48 h, by Western 
blotting. (B) MCF-7 SVV cells transfected with pcDNA or FRNK cDNA were added to Matrigel-coated 
Transwell inserts, and invaded cells stained with DAPI after 6 h (left), were quantified (right).  
***, p<0.0001. (C) MCF-7 SVV cells were treated with the indicated pharmacologic inhibitors, and 
analyzed in a Matrigel invasion assay after 6 h (D) MCF-7 SVV cells were treated with increasing doses of 
another Src inhibitor, SU6656 and analyzed in matrigel invasion assay.(E) MCF-7 SVV cells were treated 
with vehicle (DMSO) or pharmacologic inhibitors of c-Src, PP2 (left), PI3 kinase/Akt, LY294002 (middle), 
or MEK, PD98059 or U0126 (right), for 24 h, and analyzed by Western blotting  
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Figure 2-13: Cell cycle analysis after Src inhibition  
 MCF-7 SVV cells were incubated with vehicle (DMSO) or the indicated Src inhibitors, and analyzed for 
DNA content after 24 h by propidium iodide staining and flow cytometry.  The percentage of cells in the 
G1 or G2/M phase of the cell cycle is indicated.  
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Figure 2-14: Requirements of IAP-dependent tumor cell invasion  
 MDA-MB-231 cells were incubated with vehicle (DMSO) or Src inhibitor, PP2, and analyzed for invasion 
through Matrigel-coated Transwell inserts by DAPI staining (left), and quantified (right). 
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Figure 2-15: Anoikis-associated cell death  
A) MCF-7 or MCF-7 SVV cells were forced in suspension using ultra-low attachment plates, and analyzed 
at the indicated time intervals by propidium iodide staining and flow cytometry.  The percentage of cells 
with hypodiploid (apoptotic) DNA content is indicated.  (B) Cytosol extracts of MCF-7 or MCF-7 SVV 
cells adherent to substrate or in suspension (ultra-low) were analyzed by Western blotting.   
(C) MCF-7 or MCF-7 SVV maintained attached or in suspension were transfected with control (Ctrl) or 
survivin-directed (SVV) siRNA, and analyzed at the indicated time intervals by Western blotting. 
(D)Transfected MCF-7 SVV cells were analyzed after 48 h for nuclear morphology of apoptosis under 
conditions of attachment (A) or in suspension (S). For Panel D, data is mean± SD of at least two 
independent experiments.  
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Figure 2-16: Anoikis associated cell signaling 
 (A) Mitochondria (top) or cytosol (bottom) extracts of MCF-7 or MCF-7 SVV cells attached or in 
suspension (ultra-low) were analyzed by Western blotting.  (B) MCF-7 or MCF-7 SVV cells in suspension 
were analyzed at the indicated time intervals by Western blotting.  
61 
 
 
 
Figure 2-17: Requirement of fibronectin and β-1 integrin in IAP mediated tumor invasion  
A) MCF-7 SVV cells transfected with control (Ctrl) or fibronectin (Fn)-directed siRNA in suspension were 
analyzed by Western blotting. B) MCF-7 and MCF-7 SVV cells were transfected with control (Ctrl) or β-1 
integrin siRNA and analyzed by immunoblotting.  
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Chapter 3: Involvement of survivin-XIAP complex in NFκB activation 
and enhanced tumor invasion 
 
Statement of contribution 
 
The work presented in this Chapter was done in collaboration with Takehiko Dohi, 
Research Assistant Professor in our lab. Takehiko Dohi made the stable cell lines 
expressing different survivin and XIAP mutants which were extensively used for this 
study. He also performed Luciferase and the electrophoretic mobility shift assays with the 
stable cells lines as shown in Figure 3-1 and Figure 3.3. The XIAP mutants, RINGΔ, 
V80D and H467A were obtained from Colin Duckett, University of Michigan.                            
 
Introduction 
Earlier studies have shown direct interaction of survivin and XIAP under 
conditions of cellular stress which protects XIAP from polyubiquitination and 
proteasome mediated degradation in vitro and in vivo (Dohi et al., 2004). Whether this 
survivin-XIAP interaction is important in mediating some of the downstream effects of 
XIAP is not well studied. XIAP is the most well studied IAP member characterized by 
the presence of three BIR domains which directly interact with caspase 3, 7 and 9 as 
confirmed by crystal structure (Chai et al., 2001; Huang et al., 2001b; Riedl et al., 2001). 
XIAP also has a RING finger domain at the carbxy terminus which has E3 ubiquitin 
ligase activity and is responsible for ubiquitination of other target proteins including 
itself. In addition to being a caspase inhibitor, XIAP also regulates a number of other 
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signaling cascades which are caspase independent (Lewis et al., 2004). One of the 
signaling pathways regulated by XIAP is the NF-κB pathway. The mechanism that has 
been described recently for NF-κΒ activation by XIAP is through the formation of 
TAB1-TAK1 complex which leads to TAK1activation (Lu et al., 2007). TAK1 is MAP 
kinase kinase kinase (MAP3K) which phosphorylates and activates inhibitor of kB kinase 
(IKK) (Wang et al., 2001), a kinase responsible for IκΒ−α phosphorylation and 
degradation leading to nuclear translocation and activation of NF-κΒ. XIAP mediated 
ΤΑΚ1 activation has been shown to play an important role in mediating anti-apoptotic 
effects of XIAP (Lewis et al., 2004; Sanna et al., 2002) and cell survival mediated by NF-
κB (Hofer-Warbinek et al., 2000). Additionally, TAK1 activation has also been shown to 
be involved in tumor cell invasion by activation of MMPs (Safina et al., 2008).  
Fibronectin (FN), a surface glycoprotein with monomer molecular weight of 220-
240 kD is shown to be overexpressed in IAP expressing cells (this study). How the 
fibronectin expression is transcriptionally regulated in these cells is one of the key 
questions addressed in this part of the study. Several transcriptional factors and 
regulatory proteins are involved in controlling FN gene expression in tumor cell types. In 
melanoma cell lines, fibronectin has been shown to be regulated by Egr-1 transcription 
factor which gets activated by hepatocyte growth factor (HGF) induced MAP 
kinase/ERK signaling cascade (Gaggioli et al., 2005). Its expression is also regulated by 
the protein kinase C (PKC) pathway as seen in hepatoma cells where its expression is 
increased on stimulation with phorbol 12-myristate 13-acetate (PMA). More importantly 
several studies have shown that fibronectin serves as a target gene of NF-κB (Lee et al., 
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2002; Yi et al., 2000). Fibronectin contains binding sites for p65/p50 homodimer in its 
promoter region which allows the transcription factor to bind efficiently and regulate the 
transcription of FN gene (Lee et al., 2002). This is particularly important in the context of 
this study as we see activated NFκB and enhanced fibronectin expression in IAP 
expressing cells suggesting a possible correlation between the two proteins.  
In this part of the study we have extended the findings of Lu et. al. (Lu et al., 
2007) demonstrating involvement of survivin-XIAP complex in the activation of NF-κB 
through the TAB1 TAK1 complex which in turn activate fibronectin expression.  
 
Results  
IAP intermolecular cooperation activates NFκB 
In this part of the study, we focused on the upstream requirements of IAP 
induction of fibronectin, as a basis for its subsequent paracrine signaling in tumor cell 
invasion. For these experiments, we stably transfected survivin in wild type (WT) or 
XIAP-/- mouse embryonic fibroblasts, which expressed very low levels of endogenous 
survivin, and selected clones with comparable recombinant protein expression in a 
XIAP+/+ (clones #44 and #68), or XIAP-/- (clones #2 and #5) background (Figure 3-1A). 
Using this reconstitution strategy, we found that expression of survivin in XIAP+/+ cells 
(clones #44 and #68) stimulated nuclear translocation of p65 NFκB (Figure 3-1B), and a 
3-fold induction of NFκB promoter activity, quantitatively similar to TNFα treatment 
(Figure 3-1C). In contrast, survivin expression in XIAP-/- clones had no effect on NFκB 
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translocation (Figure 3-1B), or promoter activity (Figure 3-1C). However we observed 
that a radiolabeled NFκB probe binds to the nuclear extracts of XIAP+/+ cells transfected 
with survivin, by EMSA, and this reaction gets supershifted by an antibody to p65 NFκB 
(Figure 3-1D). Conversely, expression of survivin in a XIAP-/- background did not result 
in NFκB-protein complexes, by EMSA (Figure 3-1D). In ‘add-back’ experiments, 
transfection of survivin expressing XIAP-/- cells with XIAP restored the formation of 
NFκB complexes by EMSA, whereas a RING-less XIAP mutant (RING-Δ) was 
ineffective (Figure 3-1D). 
Next, we asked whether IAP stimulation of NFκB contributed to fibronectin 
expression. Accordingly, siRNA knockdown of p65 NFκB silenced endogenous p65 
expression in MCF-7 SVV cells (Figure 3-2A), and suppressed endogenous fibronectin 
levels (Figure 3-2B). In addition, TNFα stimulation strongly upregulated fibronectin 
expression in MCF-7 or MCF-7 SVV cells, albeit more prominently in survivin-
transfected cultures (Figure 3-2C), consistent with a role of fibronectin as an NFκB target 
gene. We next carried out two experiments to test a requirement of a survivin-XIAP 
complex in NFκB induction of fibronectin. First, siRNA knockdown of survivin or XIAP 
comparably suppressed endogenous fibronectin levels in MCF-7 SVV cells  
(Figure 3-2D), confirming that both molecules were required for fibronectin induction. 
Second, INS-1 cells stably transfected with wild type survivin or a survivin S20A mutant 
that constitutively binds XIAP, exhibited increased NFκB promoter activity in a reaction 
further enhanced by TNFα (Figure 3-2E). Conversely, clones of INS-1 cells transfected 
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with survivin S20E, which does not bind XIAP, had significantly reduced NFκB 
promoter activity with or without TNFα (Figure 3-2E). 
Requirement of NFκB activation by IAP intermolecular cooperation 
 To begin identifying how IAPs activate NFκB, we next focused on potential 
changes in IκBα, a negative regulator of this pathway. In reconstitution experiments with 
recombinant proteins, XIAP enhanced phosphorylation of IκBα, in vitro, and this 
reaction was further increased by addition of recombinant survivin (Figure 3-3A). 
Activation of the MAP 3 kinase, TAK1 has been implicated in this pathway via 
formation of a complex between XIAP and the adapter protein TAB1 (Lu et al., 2007), 
and subsequent phosphorylation of the IκBα kinase, IKK. Consistent with this model, 
XIAP increased IκBα phosphorylation in a reaction enhanced by the proteasome 
inhibitor, lactacystin (Figure 3.3B). In contrast, a XIAP V80D mutant that does not bind 
TAB1 (Lu et al., 2007) had no effect on IκBα phosphorylation, with or without 
lactacystin (Figure 3-3B). Additionally, transfection of WT XIAP in XIAP-/- cells 
stimulated NFκB promoter activity, whereas a XIAP Val80Asp (V80D) mutant t was 
ineffective (Figure 3-4A). 
To elucidate the structural requirements of this response, we next used XIAP 
isoforms in reconstitution experiments, in vitro. Mixed with extracts of control 
transfectants, recombinant XIAP increased IκBα phosphorylation, in vitro (Figure 3-3C), 
consistent with the data presented above. In contrast, a truncated XIAP variant lacking 
the RING domain, or two XIAP point mutants that disrupt the TAB1 binding interface 
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(V80D), or abolish XIAP E3 ligase activity (H467A) were less effective at mediating 
IκBα phosphorylation (Figure 3-3C). In parallel, we silenced TAB1 expression by 
siRNA (Figure 3-4 B), and this completely abolished XIAP-mediated IκBα 
phosphorylation regardless of the XIAP isoform tested (Figure 3-3 C), and suppressed 
NFκB promoter activity in the presence or absence of TNFα (Figure 3-3D). siRNA 
knockdown of the downstream effector of this pathway, TAK1 (Figure 3-4B), also 
suppressed NFkB promoter activity with or without TNFα (Figure 3-3D). To identify a 
role of survivin in a TAB1-TAK1 signaling axis, we next carried out co-
immunoprecipitation experiments, in vivo. Immune complexes of wild type survivin or 
survivin S20A mutant that constitutively binds XIAP contained co-associated XIAP and 
TAB1, in vivo (Figure 3-3E). In contrast, immunoprecipitates of survivin S20E mutant, 
which does not bind XIAP, were devoid of TAB1 (Figure 3-3E), suggesting that a 
survivin-XIAP complex may optimally recruit TAB1 for subsequent TAK1 activation. 
Finally, we used two complementary approaches to explore the role of this pathway in 
tumor cell invasion. In these experiments, siRNA knockdown of p65 NFκB (Figure 3-
5A) or expression of a phosphorylation-defective IκBα ‘super-repressor’ mutant (Figure 
3-5B) significantly inhibited MCF-7 SVV cell invasion through Matrigel inserts, 
compared to control transfectants. As control, expression of the IκBα mutant abolished 
NFκB promoter activity (Figure3-6), thus validating its specificity. 
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Discussion 
In this study we have shown that upstream requirement(s) for IAP induction of 
fibronectin depended on stimulation of NFκB activity in tumor cells. This pathway 
involved de novo transcription of a proximal, 1.9 kb region of the fibronectin gene, 
recapitulated by TNFα stimulation of IAP-expressing cells, and, conversely, ablated by 
siRNA knockdown of p65 NFκB, thus identifying fibronectin as a bona fide NFκB 
downstream target gene. Although a role of XIAP in NFκB activation has been 
recognized previously (Srinivasula and Ashwell, 2008), reconstitution experiments in 
XIAP-/- cells, siRNA silencing of survivin or XIAP, and analysis of survivin mutants 
differentially competent or defective to bind XIAP, identified here a novel requirement of 
survivin in this pathway. Previously, survivin was shown to form a physical complex 
with XIAP, which resulted in enhanced XIAP stability during apoptosis, and cooperative 
inhibition of caspase activity (Dohi et al., 2007). The data presented here expand this 
model, and suggest that in addition to cytoprotection, a survivin-XIAP complex may be 
also required for IAP signaling, and specifically NFκB-dependent gene expression. The 
assembly of IAP-IAP complexes may be a more general property of these molecules, 
potentially useful to add novel functional recognitions, as suggested by the interaction 
between survivin and IAP protein, BRUCE in the control of cytokinesis (Pohl and 
Jentsch, 2008). 
The mechanisms by which IAPs, typically XIAP, activate NFκB have been 
debated. Current models for this pathway are potentially operative in a highly context-
dependent manner, and involve a ubiquitination step mediated by XIAP E3 ligase activity 
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(Lewis et al., 2004), parallel activation of Smad4 signaling (Birkey Reffey et al., 2001), 
or sustained phosphorylation and degradation of the negative NFκB regulator, IκBα 
(Hofer-Warbinek et al., 2000). The data presented here are broadly consistent with these 
findings, and suggest that intermolecular cooperation between survivin and XIAP leads to 
IκBα phosphorylation as a prerequisite for NFκB activation, and subsequent fibronectin-
dependent tumor cell invasion. This pathway required the integrity of a TAB1-TAK1 
signaling axis (Lu et al., 2007) for efficient IκBα phosphorylation and subsequent 
stimulation of NFκB promoter activity, in vivo. Consistent with earlier observations 
(Lewis et al., 2004), both the RING domain of XIAP, and its intrinsic RING-associated 
E3 ligase activity were required for IκBα phosphorylation, potentially via physical 
docking with the adapter protein TAB1 (Lu et al., 2007), or a ubiquitylation step 
intercalated in IκBα phosphorylation (Lewis et al., 2004), respectively. As far as a 
potential role of survivin in this response, co-immunoprecipitation experiments presented 
here supported a model in which formation of a survivin-XIAP complex may be required 
to optimally recruit TAB1 in a ternary interaction to facilitate the downstream activation 
of TAK1, a canonical NFκB activator, (Karin and Greten, 2005), which phosphorylates 
IKK (Wang et al., 2001), by induced proximity (Lu et al., 2007). Although knockout 
studies are consistent with this model, and demonstrate that lack of TAK1 results in 
profoundly impaired activation of NFκB through the canonical pathway, the 
requirements for TAB1 in this system were less clear, with normal stimulation of NFκB 
activity observed in TAB1-/- fibroblasts (Shim et al., 2005). In this context, it is possible 
that a IAP (survivin-XIAP)-TAB1-TAK1 ternary signaling complex may be 
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preferentially exploited in tumor cells, as opposed to normal tissues, and accordingly, 
TAK1 has been recently implicated in enhanced migration and metastasis of breast 
cancer cell types (Safina et al., 2007), thus consistent with the overall findings of these 
studies.   
In this context, there is growing evidence for a role of NFκB signaling in 
metastasis, largely associated with stimulation of epithelial-mesenchymal transition 
(EMT), expression of matrix metalloproteinase-9 (MMP-9), and repression of putative 
metastasis-suppressor genes, in vivo (Naugler and Karin, 2008).  In our experimental 
system, IAP-induced NFκB activation did not result in morphological features of EMT, 
as judged by comparable expression of E-cadherin in MCF-7 or MCF-7 SVV cells, or 
changes in MMP-2 or -9 levels (Data not shown). Instead, the link between NFκB 
activation and fibronectin gene expression, with its subsequent paracrine activation of 
FAK/Src signaling and enhanced tumor cell invasion, adds a new mechanistic role of 
NFκB in tumor progression.  From a ‘translational’ perspective, this suggests that NFκB 
antagonists (Karin and Greten, 2005) may be beneficial at suppressing fibronectin levels 
in IAP-expressing tumor cells, thus impairing their invasive potential, in vivo.  This is 
consistent with proof-of-concept experiments presented here, showing that siRNA 
silencing of p65 NFκB or expression of an IκBα ‘super-repressor ‘mutant efficiently 
inhibited tumor cell invasion.  
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Figure 3-1: IAP activation of NFκB   
(A) Wild types (WT) or XIAP-/- MEFs were stably transfected with HA-tagged survivin, and independent 
clones were analyzed by Western blotting.  Cells transfected with HA-survivin cDNA were used as control. 
(B) Nuclear extracts from MEF clones expressing survivin on a WT (clones #68 and #44) or XIAP-/- 
(clones #2 and #5) background were analyzed by Western blotting.  MEFs stably transfected with GFP 
were used as control (GFP).  (C) WT or XIAP-/- clones expressing survivin were analyzed for β-
galactosidase-normalized NFκB luciferase reporter activity.  **, p=0.006.  (D) Nuclear extracts from WT 
(XIAP+/+) or XIAP-/- clones expressing survivin were incubated with a 32P-labeled NFκB probe in the 
presence of IgG or an antibody to p65 NFκB, followed by autoradiography. Arrow, position of supershifted 
band.  RLU, relative luciferase units.  For panel C data are the mean±SEM of replicates out of at least two 
independent determinations. 
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Figure 3-2: IAP mediated NFκB activation of Fibronectin  
(A, B) MCF-7 SVV cells were transfected with control (Ctrl), or p65 NFκB-directed siRNA, and analyzed 
by Western blotting after 48 h (C) Unstimulated or TNFα-stimulated MCF-7 or MCF-7 SVV cells were 
analyzed by Western blotting ( (D) MCF-7 SVV cells transfected with control (Ctrl), survivin (SVV)- or 
XIAP-directed siRNA were analyzed by Western blotting.(E) INS-1 cells stably transfected with the 
indicated survivin variants were analyzed for β-galactosidase-normalized NFκB luciferase promoter 
activity with or without TNFα. RLU, relative luciferase units. For panel E data are the mean±SEM of 
replicates out of at least two independent determinations 
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Figure 3-3: Requirements for IAP activation of NFκB.  
 (A) Extracts from MCF-7 cells incubated with recombinant survivin (SVV), XIAP, or IκBα were analyzed 
by Western blotting. Bottom, densitometric quantification of protein bands normalized to control lane.  
(B) The indicated recombinant proteins were mixed in vitro with or without the proteasome inhibitor, 
lactacystin, and analyzed by Western blotting. Right, densitometric quantification of protein bands 
normalized to control lane. Lac, Lactacystin. (C) Recombinant IκBα was incubated with total cell extracts 
of XIAP-/- DLD1 cells isolated after transfection with control (Ctrl, left) or TAB-1-directed (center) 
siRNA, and analyzed by Western blotting. Right, densitometric quantification of protein bands normalized 
to control lane. (D) MCF-7 SVV cells transfected with the indicated siRNAs were analyzed for β-
galactosidase-normalized NFκB luciferase promoter activity with or without TNFα. (E) INS-1 cells stably 
expressing the indicated survivin variants were immunoprecipitated (IP) with an antibody to survivin and 
pellets were analyzed by Western blotting. 
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Figure 3-4: Effect of XIAP mutants on NFkB-dependent transcription  
(A) XIAP-/- MEF were co-transfected with pcDNA, WT XIAP or a XIAP V80D mutant plus an NFκB 
luciferase-reporter construct, mixed with or without TNFα, and analyzed for β-galactosidase-normalized 
luciferase activity. Mean±SEM of triplicates of a representative experiment out of at least two independent 
determinations. B) MCF-7 SVV cells were transfected with control (Ctrl) or TAB1- or TAK1-directed 
siRNA, and analyzed by RT-PCR 
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Figure 3-5: Requirements of NFκB for IAP-mediated tumor cell invasion 
(A) MCF-7 SVV cells transfected with control (Ctrl) or p65 NFκB-directed siRNA were analyzed by 
immunoblotting (B) siRNA transfected cells were analyzed for Matrigel invasion after 6 h by DAPI 
staining (left panel), and quantified (right panel). (C) MCF-7 SVV cells were transfected with pcDNA or 
super-repressor IκBα mutant (IκBα-Mut) and analzed for matrigel invasion after 6hr by DAPI staining (left 
panel) and quantified (right panel).  ***, p<0.0001.  For panels, B and C, data are the mean ± SD of 
duplicates of a representative experiment out of at least two independent determinations. 
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Figure 3-6: Effect of IκBα mutant on NFκB-dependent transcription 
MCF-7 SVV cells were transfected with or without a super-repressor IκBα mutant (IκBα-Mut), and 
analyzed for NFκB-dependent luciferase activity in the presence or absence of TNFα. Mean±SEM of 
replicates of at least two independent determinations. 
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Chapter 4:  IAP mediated tumor metastasis in vivo 
 
Introduction 
Metastasis is the most fatal component of all cancers and it is the biggest hurdle to 
the effective treatment and cure of cancer. Metastasis is associated with poor prognosis 
and reduced survival rates and is the leading cause of majority of cancer mortalities. It is 
a complicated, multistep process that requires tumor cells to complete all the necessary 
steps successfully, including invasion, intravasation, survival in the circulation and 
finally colonization and growth at distant sites. To understand the process completely we 
need to use appropriate models that mimic the entire process. In vitro approaches are 
valuable in identifying genes, eliminating variability and enhancing experimental 
reproducibility but in vivo models still remain the ‘gold standard’ for understanding the 
process in its entirety. In vitro studies simply implicate whether a gene (s) is important in 
particular step(s) in a metastatic cascade but doesn’t necessarily imply that particular 
gene will help the tumor cells to complete all the steps successfully. Hence appropriate  
in vivo studies are important and required to confirm the in vitro findings and understand 
the complexity of the metastatic cascade.  
Several in vivo approaches are currently available; the most commonly used 
among them is the injection of human tumor cell lines in immunocompromised mice 
including nude mice, SCID mice, and SCID-beige mice in order to prevent immune 
rejection. For this study we have used SCID-beige mice where the T-cell and B-cell 
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function is compromised together with NK cell function (Beige mutation). Depending on 
the site of injection, these transplantable models can be divided into two broad categories.  
The spontaneous approach involves injection of tumor cells in heterotopic (or 
subcutaneous) or orthotopic sites resulting in tumor formation and ‘spontaneous 
metastasis’. This requires the tumor cells to complete all the steps of metastasis including 
invasion, escape into the circulation and growth and colonization at distant sites. Thus it 
mimics the entire metastatic process providing us with a better understanding of the 
process. For spontaneous assays, orthotopic injection (injecting at the same site from 
which the tumor was derived) is a preferred method of choice for it enhances the 
efficiency of metastasis as demonstrated by several studies using breast cancer cells 
injected in mammary fat pads (Bao et al., 1994; Levy et al., 1982), osteosarcoma injected 
in bone (Berlin et al., 1993) and prostatic cells injected in prostate (Knox et al., 1993). 
Orthotopic transplantation also  emphasizes the importance of host tumor interactions and 
tumor microenvironment in tumor progression and metastasis (Joyce and Pollard, 2009).  
The second approach involves the injection of tumor cells directly into the 
systemic circulation bypassing the initial steps of tumor invasion and intravasation. This 
is referred as ‘experimental metastases’. The common sites used for experimental 
metastasis is lateral tail vein for studying lung metastasis and intrasplenic or portal vein 
for liver metastasis. Experimental metastasis assays have several advantages over the 
‘spontaneous’ approach. Since the tumor cells are injected directly into the circulation, 
the metastatic process is rapid and the results are more consistent and reproducible. 
Secondly, they allow for more focused analysis of the later steps of the metastatic 
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cascade. Lastly, complications arising due to large primary tumor masses are avoided as 
sometimes the primary tumor burden overwhelms the animal much before the appearance 
of macroscopic metastasis. In some cases, primary tumor size strongly correlates with the 
likelihood of forming metastasis (Price et al., 1990; Safarians et al., 1996). On the other 
hand, the validity of experimental assays is highly disputed as they fail to provide a true 
picture of the entire process as they bypass two of the initial steps and key determinants 
of this process, tumor invasion and intravasation. Secondly, the importance of tumor 
microenvironment and tumor host interactions are not represented in experimental assays 
which makes spontaneous assays more ideal, better suited and more efficient way of 
studying metastasis. 
In this study, we chose to use an intrasplenic injection model in which the cells 
were injected in the spleen and monitored for liver metastasis. This approach is well 
suited and has been shown to be better than both spontaneous or experimental assays for 
studying metastasis for various cell lines tested like colon , prostate, melanoma and 
adenocarcinomas (Kozlowski et al., 1984). It facilitates tumor growth and metastasis in a 
number of ways that include 1) the absence of a pseudocapsule at the site of injection 2) 
direct access to the portal vein hence mimicking experimental metastasis to some extent 
3) formation of multifocal secondary metastases which characterizes a spontaneous or 
subcutaneous assay 4) enhanced survival of tumor cells as compared to systemic injection 
and 5) providing suitable environment for tumor dissemination as observed in certain 
tumor cells (Kozlowski, 1995) 
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Results 
Intrasplenic injection of breast cancer cells stably expressing survivin  
To test whether IAP-dependent tumor cell invasion promotes metastasis, in vivo, 
we used a liver metastasis model in which tumor cells were injected into the spleen of 
immunocompromised SCID/beige mice; 24hrs later splenectomy was performed to 
remove the primary tumor mass and mice were monitored for colonization of the liver.  
Intrasplenic injection of MCF-7 cells in SCID/beige mice did not result in significant 
liver metastasis, by bioluminescence imaging (Figure4-1A). In contrast, MCF-7 SVV 
cells injected in the spleen of immunocompromised mice gave rise to extensive 
metastatic localization of the liver within the same time interval (Figure 4-1A, B). 
Consistent with this, histologic analysis of livers harvested from mice injected with 
MCF-7 SVV cells, but not MCF-7 cells, revealed the presence of multiple metastatic 
nests of epithelial cells  (Figure 4-1C). 
Intrasplenic injection of HCT116 XIAP-/-  
 To determine whether a survivin-XIAP complex was required for the metastatic 
phenotype, we next injected wild type (XIAP+/+) or XIAP-/- HCT116 cells in the spleen of 
SCID/beige mice.  Within a 3-week interval, animals injected with XIAP+/+ cells 
exhibited massive metastatic colonization of the liver with nearly complete substitution 
of the hepatic parenchyma by the tumor cell population (Figure4-2).  In contrast, XIAP-/- 
cells did not significantly metastasize to the liver (Figure 4-2), indicating an absolute 
requirement of XIAP for this response. 
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Intrasplenic injection of insulinoma cells overexpressing survivin and Bcl2  
Because both survivin and XIAP inhibit apoptosis, we next wished to determine 
whether the metastatic phenotype of MCF-7 SVV cells was mediated by IAP-dependent 
tumor cell invasion, as described above, or simply reflected enhanced cell survival. To 
discriminate between these two possibilities, we injected SCID/beige mice with INS-1 
cells stably transfected with survivin or anti-apoptotic Bcl-2, which in previous 
experiments promoted exponential growth of superficial xenograft tumors, thus 
confirming its activity (Dohi et al., 2007). Here, animals injected with INS-1 cells or 
INS-1 stably expressing Bcl-2 did not show changes in blood glucose levels, used as a 
marker of aberrant insulin production (Figure 4-3A), and produced no or very few liver 
metastases respectively (Figure 4-3C,D). In contrast, INS-1 cells stably transfected with 
survivin, INS-SVV caused dramatic and time-dependent decrease in systemic blood 
glucose level in reconstituted animals, (Figure 4-3A), and this was associated with 
extensive metastatic dissemination of insulin-producing tumor cells to the liver (Figure 4-
3B,C). 
Discussion 
In this part of the study we provide evidence of the importance of IAP mediated 
tumor metastasis in vivo. We use intrasplenic injection model for this study as this 
approach for it allows for an unbiased evaluation of metastatic dissemination, not 
confounded by the growth of a primary tumor since the spleen containing the primary 
tumor mass is resected after 24hrs. Using this approach, we demonstrate that expression 
of survivin and XIAP was sufficient to promote rapid and extensive tumor cell 
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colonization of the liver, in vivo. We have confirmed the metastatic phenotype in two 
independent cell lines stably expressing survivin, MCF-7 SVV and INS-SVV suggesting 
that survivin play an important role in the metastatic process of various different kinds of 
tumors and is not a cell type specific phenomena. Although it remains to be seen whether 
the higher levels of fibronectin in MCF-7 SVV and INS-SVV cells contribute to this 
metastatic phenotype, it is clear that both survivin and XIAP are indispensable for this 
response, given the complete lack of metastatic potential of HCT116 XIAP-/- in this 
animal model. This is consistent with retrospective analysis of patient series that have 
consistently associated the expression of survivin and XIAP with aggressive tumor 
behavior and unfavorable disease outcome, in vivo (Hinnis et al., 2007). In addition, IAP-
mediated metastasis was independent of the cytoprotective function of these molecules, 
as expression of anti-apoptotic Bcl-2 could not substitute for survivin in the animal 
studies, and did not result in systemic tumor growth and appreciable metastatic 
dissemination to the liver. Previous studies had also suggested that IAP activation of 
NFκB (Lu et al., 2007) is structurally and functionally separable from its role in caspase 
inhibition (Lewis et al., 2004), and, accordingly, transgenic expression of survivin 
resulted in increased rates of metastatic dissemination in a melanoma mouse model, 
potentially independent of its role in cytoprotection (Thomas et al., 2007).  
To conclude, this part of the study confirms the in vitro findings of IAP mediated 
tumor invasion and suggests an important role of these molecules in regulating tumor 
dissemination by bringing about gene expression changes which help tumor cells to 
successfully complete the metastatic journey.  
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Figure 4-1: IAP-mediated metastasis, in vivo using breast cancer cells  
A) MCF-7 or MCF-7 SVV cells stably transfected with a luciferase cDNA were intrasplenically injected in 
SCID/beige mice and analyzed by bioluminescence imaging at the indicated time intervals after injection.  
B) Livers from mice intrasplenically injected with MCF-7 or MCF-7 SVV cells stably transfected with 
luciferase were harvested at d. 11 after injection, and analyzed by bioluminescence imaging.  Right, 
quantification of fluorescence signals. C)  Livers from representative animals (#) injected with MCF-7 or 
MCF-7 SVV cells transfected with luciferase were harvested at d. 11, formalin-fixed, paraffin-embedded, 
and analyzed histologically by hematoxylin-eosin staining and light microscopy. Arrows, metastatic foci. 
Magnification, x200,x100.  
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Figure 4-2: XIAP mediated tumor metastasis using colorectal cancer cells 
XIAP+/+ or XIAP-/- HCT116 cells were injected in the spleen of SCID/beige mice, and resected 
livers were examined macroscopically after 3 weeks 
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Figure 4-3: IAP-mediated liver metastasis in vivo using insulinoma cells 
A) SCID/beige mice were injected in the spleen with INS-1 cells expressing survivin or Bcl-2 and 
monitored for blood glucose levels at the indicated time intervals. B) Livers of animals injected in the 
spleen with INS-1 survivin transfectants were harvested after 3 weeks, and stained for insulin or H&E.  
IgG, non binding antibody. Each bar represents metastatic foci/mice. Arrows, metastatic foci.  
Magnification, x100. C) Quantification of liver metastases by INS-1 cells.  Metastatic foci were counted 
blindly in four independent microscopy fields of serial liver sections harvested from the indicated animal 
groups. *, p=0.017-0.025. D) H&E staining of livers of Wild type INS-1 cells or INS-1 cells stably 
transfected with anti-apoptotic Bcl-2.  Arrows, metastatic foci.  Magnification, x100. 
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Chapter 5:  Materials and Methods 
Cells and cell culture  
Wild type or XIAP-/- mouse embryonic fibroblasts (MEF) were the generous gift 
of Dr. Colin Duckett (University of Michigan, School of Medicine).  Colorectal 
adenocarcinoma HCT116 cells, XIAP-/- HCT116, and XIAP-/- DLD1 were kindly 
provided by Dr Bert Vogelstein (Johns Hopkins Medical Institutions) and cultured in 
McCoy’s media (GIBCO) with 10% fetal bovine serum (FBS) and 1% pen-strep 
(GIBCO).  Breast adenocarcinoma MDA-MB-231 cells were obtained from the 
American Type Culture Collection (ATCC), and cultured in Dulbecco’s modified eagles 
medium (GIBCO) with 10% fetal bovine serum (FBS) and 1% pen-strep (GIBCO).  
Prostate adenocarcinomas cells,PC3 and breast adenocarcinomas cells, SUM159 were 
kindly provided by Dr. Lucia Languino and Dr.Leslie Shaw (University of 
Massachusetts, Worcester) respectively. They were grown as per ATCC 
recommendations.  The rat insulinoma cell line INS-1 was the kind gift of R.S. Sherwin 
(Yale University School of Medicine).  
Generation of stable cell lines 
For generation of MCF-7 SVV stable cell line, breast adenocarcinoma MCF-7 
cells were stably transfected with pcDNA3 or a survivin cDNA, transferred to a 100-mm 
dish in selection medium containing 1 mg/ml G418 (GIBCO), and colonies were isolated 
2-3 weeks later. For mice experiments, parental MCF-7 or MCF-7 SVV cells were 
transfected with pcDNA4/V5-His containing an HA-tagged luciferase cDNA, by 
Lipofectamine, and stable clones were selected in medium containing 800 μg/ml Zeocin 
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(Invitrogen) for 3 weeks.  Expression of luciferase in stably transfected cells was 
confirmed by bioluminescence imaging using an IVIS-100 camera system (Xenogen, 
Alameda, CA).  Recombinant protein expression in the various selected clones was 
confirmed by Western blotting.  
For generation of XIAP shRNA stable clones, five Human pLKO.1 lentiviral 
shRNA plasmids for XIAP (pLKO.1-XIAP) were obtained from OpenBiosystems  
(cat#; RHS4533-NM_001167). The shRNA expressing  lentivirus were cotransfected 
with 0.5 μg of pLKO.1-XIAP or pLKO.1 (control), 0.33 μg of pCMVdel8.2 and 0.2 μg of 
pMDG (VSVG envelope glycoprotein)  in 293T cells using Lipofectamine 2000 using a 6 
well format. Retroviral supernatant were harvested 48hours after transfection, followed 
by filtration through a 0.45-μm-pore-size filter. Infections were carried out in the 
presence of 4 μg/ml of polybrene, and cells were selected with 1 μg/ml puromycin for at 
least one week. 
For generation of  Ins-1 stable cell lines, INS-1 cells were stably transfected with 
pcDNA3, wild type survivin, survivin Ser20Ala (S20A) or Ser20Glu (S20E) mutant, or 
Bcl-2, by Lipofectamine (Invitrogen, 4 μl/well), and clones were selected in medium 
containing 0.8 mg/ml G418 (Invitrogen), and well characterized in previous studies (Dohi 
et al., 2007) 
RNA quantification 
Total RNA was isolated from MCF-7 or MCF-7 SVV cells using RNeasy Mini 
Kit (Qiagen, Valencia, CA), and cDNA was synthesized using a SuperScript™ First-
Strand synthesis system (Invitrogen, Carlsbad, CA), according to the manufacturer's 
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instructions.  Quantitative real time PCR amplification was carried out by TaqMan® 
detection (Applied Biosystems, Foster City, CA) using the following human and rat 
primers: fibronectin (Hs01549940_m1), laminin-5 (Hs00245699_m1, collagen type I α1 
(Hs00164004_m1), collagen type V α2 (Hs00169768_m1), GAPDH (Hs99999905_m1), 
rat fibronectin (Rn00569575_m1), rat laminin-5 (Rn01415966_g1), rat collagen type 1 
α1(Rn00801649_g1), and rat GAPDH (Rn99999916_s1).  Relative gene expression 
values were calculated by the ΔΔCt method. 
Western blotting and antibodies   
Cells were harvested and lysed in 20 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 
10% v/v glycerol, 50 mM NaF, 1 mM Na3VO4, plus protease inhibitors (Roche Applied 
Science, Indianapolis, IN).  Aliquots of cell extracts (30-50 μg) were separated by SDS 
gel electrophoresis, transferred to nylon membranes, and blocked with 5% dry milk in 
Tris-buffered saline, 0.1% Tween 20 (TBS-T) for 1 h at 4°C.  Samples were incubated 
with various primary antibodies for 18 h at 4°C in 5% dry milk in TBS-T, washed and 
further mixed with horseradish peroxidase-conjugated secondary antibodies (Amersham) 
for 1 h at 22°C.  Protein bands were detected by enhanced chemiluminescence 
(Amersham), and quantified by densitometry. 
In some experiments, conditioned medium was collected from MCF-7 or MCF-7 
SVV cells (2x105) after 48 h, concentrated by centrifugation using 100 kD cutoff filters 
(Millipore Inc, USA), and analyzed by Western blotting.  Aliquots of conditioned 
medium were normalized to cell number prior to loading the gel.  The following 
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antibodies were used: fibronectin (1:1000, H-300, Santa Cruz; and function-blocking 
3E3, Chemicon), β1 integrin (1:1000, C-18, BD Transduction Laboratories; and function-
blocking P4C10, Chemicon), survivin (1:1000, Novus Biologicals), 14-3-3β (1:5000, 
Santa Cruz), Bcl-2 (1:1000, Santa Cruz), XIAP (1:1000, BD Transduction), β-actin 
(1:5000, clone AC-15, A5441, Sigma-Aldrich), focal adhesion kinase (FAK) (1:1000, C-
20, Santa Cruz), Tyr397-phosphorylated FAK (p-FAK) (1:1000, Biosource 
International), c-Src (1:1000, Santa Cruz), Tyr416-phosphorylated Src (p-Src) (1:1000; 
Biosource International), p44,42 MAP kinase (ERK) (1:1000, Santa Cruz), 
Thr202/Tyr204-phosphorylated ERK (p-ERK) (1:1000, Cell Signaling), TAB1 (1:1000 
Santa Cruz), Akt and Ser473-phosphorylated Akt (1:1000, Cell Signaling), p65 subunit of 
NFκB (1:1000, Santa Cruz), IκBα (1:1000, Santa Cruz), and p-IκBα(1:1000, Cell 
Signaling), Smac (Novus Biologicals, 1:1000), and cytochrome c (Clonetech, 1:100). 
 
Transient transfections 
 For gene silencing by small interfering RNA (siRNA), various cell types were 
transfected with control non-targeted, or double-stranded RNA oligonucleotides (100 
nM/well, Dharmacon) directed to p65 NFκB (SMART pool L-003533-00-0010), 
fibronectin (SMART pool L-009853-00), XIAP (SMART pool M-004098-01-0020), 
TAB1 (SMART pool M-004770-02-0005),TAK1 (SMART pool M-003790-06-0005) or 
survivin using Oligofectamine (3 µl/well), as described (Dohi et al., 2007).  For DNA 
transfections, 4 μg of plasmid DNA was transfected in the various cell types using 
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Lipofectamine 2000 (Invitrogen, 6 μl/well).  After 24 h at 37°C, cells were washed, and 
analyzed for protein expression by Western blotting or RT-PCR. 
Immunofluorescence 
MCF-7 or MCF-7 SVV cells grown on optical grade glass coverslips in 
fibronectin-depleted medium were fixed in 4% paraformaldehyde for 30 min at 4°C, and 
permeabilized with 0.5% Triton X-100 in PBS, pH 7.4, for 30 min at 22°C.  After 
blocking with 3% BSA plus 0.2% Tween 20 in PBS, pH 7.4, samples were incubated 
with an antibody to fibronectin for 1 h at 22°C, mixed with an FITC-conjugated 
secondary antibody, and mounted with Vectashield mounting medium containing DAPI 
(Vector Laboratories, Burlingame, CA).  Slides were analyzed under a fluorescence 
microscope (Axioplan 2, Zeiss) equipped with a charge-coupled device camera 
(Axiocam, Zeiss).  In some experiments, MCF-7 or MCF-7 SVV cells were fixed in 4% 
paraformaldehyde, stained with Texas red-phalloidin (1:200, Molecular probes), and 
analyzed by fluorescence microscopy.  Images were analyzed using Photoshop CS2. 
Immunoprecipitation 
 For immunoprecipitation, cells were lysed in immunoprecipitation buffer (IP 
buffer) containing 50 mM Tris, pH 7.5, 50 mM NaCl, 1% Nonidet P-40, 0.1% CHAPS, 
plus protease inhibitors (Roche Applied Science), and 1 mM Na3Vo4 and  50mM NaF. 
The cell lysates were incubated with IgG or an antibody to TAB1 or TAK1 and the 
immune complexes were precipitated by the addition of protein A-Sepharose beads 
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(Amersham Biosciences). After washing in IP buffer, pellets or supernatants were 
separated by SDS-gel electrophoresis and analyzed by Western blotting. 
Cell proliferation and anoikis assays  
MCF-7 or MCF-7 SVV cells were analyzed for cell proliferation using an MTT 
assay in the presence of 1 mg/ml thiazolyl blue tetrazolium bromide (Sigma-Aldrich), 
and quantification of absorbance at 595 nm, as described (Dohi et al., 2007).  For analysis 
of anoikis-associated apoptosis, MCF-7 or MCF-7 SVV cells were grown on ultralow 
attachment plates (Costar), harvested at increasing time intervals (d. 2-5) at 37°C, and 
analyzed for DNA content by propidium iodide staining and flow cytometry.  Data were 
analyzed using FlowJo software, and the cellular fraction with hypodiploid, i.e. sub-G1, 
DNA content was quantified (Dohi et al., 2007). In some experiments, mitochondrial 
fractions were isolated from MCF-7 or MCF-7 SVV cells using a mitochondria isolation 
kit (Pierce, IL).  Cytosol fractions or mitochondrial pellets were dissolved in lysis buffer 
and processed by Western blotting. 
Adenoviral transduction 
 A replication deficient adenovirus (pAd) encoding wild type survivin (pAd-
Survivin) or GFP has been described (Dohi et al., 2007).  A replication-deficient 
adenovirus encoding a survivin T34A/C84A double negative mutant was obtained using 
the pAdEasy system.  To construct the shuttle vector, a HindIII/XbaI fragment of 
pcDNA3.0-T34A/C84A generated by site-directed mutagenesis using the QuickChange 
Site-Directed Mutagenesis Kit (Stratagene) was inserted into pAdTrack-CMV to generate 
92 
pAd-survivin-T34A/C84A.  The shuttle vector was linearized with PmeI, electroporated 
in E.Coli BJ5183 for homologous recombination, and colonies were selected in 50 μg/ml 
kanamycin.  Each pAd construct (4-8 μg) was digested with PacI, transfected in 
HEK293T cells by Lipofectamine, and cultures were analyzed for GFP expression, by 
fluorescence microscopy.  High-titer viral stocks were generated by Adeno-X Virus Mini 
Purification Kit (Clontech), and the viral titer was quantified by green fluorescence 
forming units in HEK293T cells infected with serial dilution of the viral stock.  Target 
cultures were transduced at a multiplicity of infection (moi) of 50 for 8 h at 37°C in 
complete medium, washed with PBS, pH 7.4, and replenished with complete medium.  
Cells were analyzed after additional 48 h at 37°C, and the transduction efficiency (>90% 
of the cell population) was estimated by GFP expression and fluorescence microscopy. 
Promoter activity 
Various cell types were transfected with an NFκB-responsive element fused to 
luciferase, or, alternatively, with a 1.9 kb fragment of the fibronectin promoter fused to 
luciferase (pGL-Fib1900), using Lipofectamine 2000.  A total of 4ug of DNA was used 
and after 24 h at 37°C, cultures were harvested, and analyzed for β-galactosidase-
normalized luciferase activity in a luminometer. In some experiments, MCF-7 SVV cells 
were transfected with control, TAB1- or TAK1-directed siRNA, and analyzed for NFκB 
luciferase promoter activity after 24 h. 
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Cell migration and invasion assays  
 Analysis of cell migration was carried out using 6.5-mm Transwell chambers (8-
μm pore size; Costar).  Inserts were prepared by coating the upper and lower surfaces 
with 15 µg/ml collagen (Cohesion, Palo Alto, CA) for 18 h at 4°C, followed by a 
blocking step with DMEM containing 0.25% heat-inactivated BSA for 1 h at 37°C. The 
various cell types were harvested, suspended in DMEM containing 0.25% heat-
inactivated BSA, and added (1x105) to the upper chamber, with aliquots of conditioned 
medium collected from NIH3T3 fibroblasts placed in the lower chamber as 
chemoattractant. After a 1 h incubation, non-migrating cells were removed mechanically 
from the upper chamber using a cotton swab. Cells migrated to the lower surface of the 
Transwell membrane were fixed in methanol for 10 min at 22°C, and membranes were 
mounted on glass slides using Vectashield mounting medium containing DAPI (Vector 
Laboratories, Burlingame, CA). Cell migration was quantified by counting the number of 
stained nuclei in five individual fields in each transwell membrane, by fluorescence 
microscopy, in duplicate. 
For analysis of cell invasion, the upper transwell chamber (8-μm pore size; 
Costar) was coated with 0.5 µg Matrigel (Collaborative Research, Bedford, MA) diluted 
in cold water, and allowed to air dry. After incubation with DMEM for 1 h, the various 
cell types (1x105) were added to the upper chamber for 6-24 h at 37°C. Cells that had 
invaded the lower surface of the membrane were fixed with methanol, stained with 
DAPI, and quantified by fluorescence microscopy. In some experiments, cells were 
incubated with the following pharmacologic inhibitors of Src (PP-2, 50 μM; SU6656, 25-
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50 μM), MEK (PD98059, 50 μM, or U0126, 25 μM), PI3 kinase (LY290042, 50 μM), or 
vehicle (DMSO) for 1 h at 37°C, added to Matrigel-coated membranes, and analyzed for 
cell invasion by fluorescence microscopy.  
Recombinant protein expression 
cDNA constructs encoding recombinant full-length survivin (residues 1-142), 
full-length XIAP, Val80Asp XIAP mutant (V80D) (Lu et al., 2007), or full length IκBα 
RING-less XIAP (RING-Δ, residues 1-442), or E3 ligase-deficient XIAP His467Ala 
mutant(Addgene) were amplified by PCR, confirmed by DNA sequencing and cloned 
into the pGEX-4T1 expression vector without or with an HA-tag epitope.  The various 
constructs were expressed as GST fusion proteins in BL-21 E.Coli, with removal of the 
GST frame by thrombin cleavage for 1 h at 37°C, followed by neutralization with 
benzamidine. 
Electrophoretic Mobility Shift Assay (EMSA) 
Twenty μg of nuclear extracts prepared from wild type or XIAP-/- MEF stably 
transfected with survivin were incubated without or with TNFα in the presence of 32P γ-
labeled 45-mer double-stranded NFκB oligonucleotide derived from the human 
immunodeficiency virus long terminal repeat, 5'-
CGCTGGGGACTTTCCAGGGAGGCGTGG-3'. Incubations were carried out in buffer 
containing 10 mM Tris HCl, pH 8.0, 150 mM KCl, 0.5 mM EDTA, 0.1 % Triton-X 100, 
12.5 % glycerol (v/v), 0.2 mM DTT for 1 h at 22°C.  Poly-dIdC (Sigma) and sonicated 
salmon sperm DNA (Stratagene) were added to block non-specific binding.  DNA-
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protein complexes were separated by electrophoresis on 5% native polyacrylamide gels, 
and radioactive bands were visualized by autoradiography.  A double-stranded 32P γ-
labeled mutant oligonucleotide, 5'-
TTGTTACAACTCACTTTCCGCTGCTCACTTTCCAGGGAGGCGTGG-3', or wild 
type unlabeled oligonucleotide was used in competition experiments.  In some 
experiments, DNA-protein complexes were incubated with an antibody to p65 NFκB for 
1 h at 22°C, and samples were analyzed by autoradiography. 
Modulation of IκBα phosphorylation 
Recombinant IκBα (0.5 μg) was mixed with extracts of XIAP-/- DLD1 cells after 
transfection with control siRNA or TAB1-directed siRNA (5 μg) in the presence of 
recombinant XIAP, XIAP RING-Δ, XIAP V80D or H467A mutant (1 μg) in buffer 
containing 40 mM Tris, pH 7.4, 5 mM MgCl2, 1 mM DTT, 50 mM ATP for 20 min 
30°C. Modulation of IκBα phosphorylation under the various conditions tested was 
analyzed with a phospho-IκBα antibody by Western blotting, and quantified by 
densitometry. For some IκBα phosphorylation studies, cells were incubated with 
proteasome inhibitor, lactacystin (1µM, Calbiochem, Cat # 426100).  
In vivo metastasis model.   
All experiments involving animals were approved by an Institutional Animal Care 
and Use Committee. Female SCID/beige mice (6-8 wk of age) were anesthetized with 
ketamine hydrochloride, the abdominal cavity was exposed by laparotomy, and animals 
were injected in the spleen with parental MCF-7 or MCF-7 SVV cells (2x106) stably 
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transfected with a luciferase cDNA. To avoid potential confounding effects on metastasis 
by the continuous growth of a primary tumor, the spleen was removed 24 h after injection 
of the tumor cells. The incision was closed in two layers with vicryl 5/0 and wound clips. 
On d 1, 3, 7, and 11 after injection, animals were analyzed for metastatic dissemination to 
the liver by bioluminescence imaging using an IVIS-100 camera system for detection of 
luciferase expression (Xenogen, Alameda, CA). Briefly, mice were anesthetized with 
isoflurane and intraperitoneally injected with 2.2 mg luciferin sodium salt (GOLD Bio 
Technology, Inc) in PBS, pH 7.4. During image acquisition, isoflurane anesthesia was 
maintained using a nose cone delivery system.  Both supine and prone images were 
scanned for a 3 min acquisition interval. Each image was acquired sequentially three to 
four times, and data were collected at the time of peak luminescence.  The 
bioluminescence images were overlaid on black and white photographs of the mice 
collected at the same time.  Signal intensity was quantified as the sum of all detected 
photon counts within a region of interest using Living image software (Xenogen, version 
2.50). On d 11, all mice in the two groups were sacrificed and their livers were resected, 
and analyzed by bioluminescence, ex vivo. In some experiments, wild type (XIAP+/+) 
HCT116, XIAP-/- HCT116 (five animals/group), wild type INS-1 (4 animals), or INS-1 
stably transfected with survivin (6 animals) or Bcl-2 (five animals) were injected (5x106 
cells) in the spleen of SCID/beige mice, followed by splenectomy as described above. 
Mice were monitored for blood glucose content twice weekly, and sacrificed after 3 
weeks. 
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Histology 
Livers from the various animal groups reconstituted as above were fixed in 
buffered formalin, and embedded in paraffin. For insulin staining, sections were 
deparaffinized, rehydrated in water, and quenched for endogenous peroxidase. Epitope 
heat retrieval was carried out by steaming the slides in 10% sodium citrate for 20 min.  
Processed slides were rinsed in PBS, pH 7.4, and stained with an antibody to insulin 
using standard avidin-biotin-peroxidase technique (Histostain-plus, Zymed Laboratories). 
Slides were incubated with DAB as a chromogen and counterstained with hematoxylin.  
Control sections were processed as above with non binding IgG, and resulted in no 
detectable staining.   
Statistical analysis 
Data were analyzed using the unpaired t test on a GraphPad software package for 
Windows (Prism 4.0). A p-value of 0.05 was considered as statistically significant. 
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Chapter 6: Final thoughts and Future directions 
 
Tumor metastasis, the leading cause of 90% of cancer deaths is one of the greatest 
unresolved mysteries of cancer research (Gupta and Massague, 2006). Research over the 
past several years has helped us in understanding the molecular mechanisms involved in 
tumor progression although metastasis, being so complex, still remains a ‘big black 
box’(Eccles and Welch, 2007). There are no therapies currently available that focus 
primarily on the metastatic aspect of the tumors. Classical treatments for tumor 
metastasis are similar to the therapies used to target primary tumors which are radiation 
therapy or chemotherapy (Steeg, 2006). In an era of targeted therapy which is based on 
molecular mechanisms we need to understand new aspects in order to get a better 
understanding of the metastatic cascade so as to devise novel therapeutic strategies to 
fight metastasis. Gene expression profiling of the metastatic tumors has helped us in 
identifying interesting targets and provided useful insights about the regulation of 
different steps of metastasis (Ramaswamy et al., 2003). Some of these studies have 
clearly demonstrated the involvement of apoptosis regulators in tumor progression  
(Um et al., 2004) . For example, on comparing various human or mouse cancer cell lines, 
an inverse correlation has been demonstrated between apoptotic sensitivity and the 
metastatic ability of the cells when injected into nude mice (Glinsky et al., 1997). Hence, 
the classical view is that apoptosis regulation is one of the key regulatory mechanisms 
required by tumor cells to form distant metastasis. 
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For my thesis research, I have demonstrated that some of the anti-apoptotic 
proteins particularly survivin play a bigger and broader role in metastasis by upregulating 
a broad gene expression program leading to the upregulation of certain cell adhesion 
molecules. We have shown that survivin mediated gene regulation requires 
intermolecular co-operation between survivin and its related cofactor, XIAP leading to 
activation of NFκB pathway. Although a role of XIAP in NFκB activation has been 
recognized previously (Srinivasula and Ashwell, 2008), our studies have identified a 
novel requirement of survivin in this pathway. We have dissected the structural 
requirements of survivin-XIAP mediated NFκB activation and demonstrated that 
synergistic cooperation of survivin and XIAP leads to enhanced IκB-α phosphorylation 
(Figure 3-3A), a prerequisite for NFκB activation. This pathway depends on the integrity 
of TAB1-TAK1 axis (Lu et al., 2007) for phosphorylation of Iκbα and stimulation of 
NFκB promoter activity in vivo. Once NFκB is activated, it leads to upregulation of 
several target genes, one of which is fibronectin which has been identified by this study 
and other studies (Lee et al., 2002) to be a bona fide NFκB target. Activation of 
fibronectin gene expression initiates the outside-in signaling by engaging with their 
cognate receptors, integrins. This leads to the activation of cell motility kinases, focal 
adhesion kinase (FAK) and Src kinases, the downstream mediators of IAP mediated 
tumor invasion and metastasis. Taken together our study has confirmed the importance of 
IAPs in tumor dissemination and dissected the upstream and downstream requirements of 
IAP mediated metastasis (Figure 6-1).  
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Figure 6-1: Model for IAP mediated tumor invasion 
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 Survivin has been shown to function as an upstream regulator of gene expression. 
Survivin, a unique member of the IAP family mediates many diverse roles ranging from 
cell death inhibition, mitotic regulation and cell cycle checkpoint surveillance (Altieri, 
2006). Due to its involvement in multiple signaling pathways involved in tumor 
maintenance, it has been rightly mentioned by Altieri et. al. (Altieri, 2008) as a classical 
nodal protein which can be utilized for targeted drug discovery. The main networks 
described are cell division and the cell death networks (Altieri, 2008). Our data adds a 
completely novel component to the existing networks of survivin and demonstrates for 
the first time the mechanistic role of survivin in the transcriptional control of cell 
adhesion molecules by activation of a broad transcription factor, NFκB (Figure 6-2). 
Because of the diverse roles of survivin, it is difficult to say which function of 
survivin is playing an important role in tumor progression and metastasis in vivo. In our 
analysis, we have shown that metastatic role of survivin is independent of its anti-
apoptotic function as we observe significant increase in invasion in Ins-1 cells 
overexpressing survivin (Ins-SVV) in vitro (Figure 2-5 B) and extensive metastasis in 
vivo (Figure 4-3) . Ins-SVV cells does not inhibit apoptosis due to defective 
mitochondrial import system (Dohi et al., 2007). Similar paradigm is applied to XIAP, as 
disruption of its anti-apoptotic function by transfecting XIAP Asp143Ala/Trp310Ala 
double mutant (D143A/W310A) that does not bind caspase 3 (D143A mutation), nor 
caspase 9 (W310A mutation) in a XIAP-/- HCT116 cells (Lewis et al., 2004) shows 
significant invasion (Figure 2-5D). This is suggestive that the anti-apoptotic function of 
IAPs is not essential for promoting metastasis although we still need further evidence in 
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vivo to solidify the findings and differentiate the anti-apoptotic functions and metastatic 
functions of IAPs. Survivin has also been extensively studied as a mitotic gene and 
shown to be a part of the chromosome passenger complex (Adams et al., 2001). Our data 
does not address if the mitotic function is essential in survivin-mediated tumor invasion 
and metastasis. This can be addressed in several ways one of which may be using a 
dominant negative Survivin mutant (Surv-DD70, 71AA) that has been reported to disrupt 
the interaction of Survivin with Aurora B, resulting in failed cytokinesis and cell division 
defects (Cao et al., 2006). It will be interesting to explore if the cells carrying this mutant 
are able to invade and metastasize.  
Moreover, in this study we have looked for the role of survivin in metastasis with 
respect to tumor invasion but failed to look at the migratory and cytoskeletal changes that 
are potentially involved and important in IAP mediated metastasis. We performed a 
phalloidin staining for actin cytoskeleton in MCF-7 SVV cells and MCF-7 cells and did 
not observe any significant changes (Figure 2-1E). However, a better approach would be 
to perform a time lapse study on IAP overexpressing cells in order to better understand 
the changes in actin modifications. Additionally, studying the changes in the activity of 
some of the proteins important in cell migration like Rho and Rac in IAP overexpressing 
cells will be useful to strengthen our observations.  
The current study utilizes the intrasplenic injection model to test the IAP mediated 
tumor metastasis in vivo. In this model, the spleen is resected after 24hrs of injection and 
liver metastasis is monitored for a period of 14-21 days. This model has given us 
promising results but we cannot overlook the potential pitfalls of this model system.  
103 
 
 
 
Figure 6-2: Connectivity map showing various diverse function of survivin  
 
As shown in this map, survivin functions in cell death, mitotic regulation, checkpoint point regulation, 
subcellular trafficking. In addition to these, the work described in this thesis describes a new role of 
survivin in transcriptional control of transcription factor, NFκB. CDK1, cyclin-dependent kinase 1; CRM1, 
chromosome region maintenance protein 1; HSP90, heat shock protein 90; INCENP, inner centromere 
protein antigens; MCAK, mitotic centromere-associated kinesin; MEN, mitotic exit network; PKA, protein 
kinase A; SGO2, shugoshin 2. This Figure is modified from  (Altieri, 2008). 
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Firstly, since spleen is a highly vascular organ and is rich in sinusoids (Cesta, 
2006), it is highly likely that the cells are injected into the sinusoids of the spleen and 
hence enter into the circulation immediately thus bypassing the initial steps of metastasis. 
We have not ruled out this possibility but our initial experiments done for protocol 
approval from IACUC (Institutional Animal Care and Use Committee) have shown that 
resecting spleen after 1 hour of injection does not result in liver metastasis (data not 
shown) suggesting that not all cells have escaped into the circulation or the few cells that 
have escaped are not viable. We lack the data showing the viability of the transfected 
cells in the spleen. It is possible that the differences in tumor metastasis are arising 
because of differences in the viability of these cells in spleen. However, we have 
investigated the proliferation kinetics of cells injected into the spleen (Fig. 2-1) and we 
did not observe any significant changes but it will be useful to know if they show similar 
kinetics in vivo. Additionally, we have performed bioluminescence imaging of mouse 
injected with MCF-7 and MCF-7 SVV cells after 24hrs of injection and immediately 
before resection and we did not observe any changes in the cell viability (Figure 6- 3). 
However, to further confirm our findings, it will be useful to isolate the cells from 
resected spleens and perform cell viability assays in vitro.  
Secondly, in our intrasplenic injection model system, we resected the spleens in 
order to remove the primary tumor so as to allow for an unbiased evaluation of metastatic 
dissemination, not confounded by the growth of a primary tumor. It was done to avoid 
the complications arising due to large primary tumor masses as sometimes the primary 
tumor burden overwhelms the animal much before the appearance of macroscopic  
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Figure 6-3: Intrasplenic injection of survivin-over expressing cells  
MCF-7 or MCF-7 SVV cells stably transfected with a luciferase cDNA.were analyzed by bioluminescence 
imaging 24hrs after injection and immediately before splenectomy. Ventral view (left) and dorsal view 
(right) 
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metastasis. Moreover, in some cases, primary tumor size strongly correlates with the 
likelihood of forming metastasis (Price et al., 1990; Safarians et al., 1996). However, 
interestingly, there are some studies that have shown a rapid outgrowth of metastasis after 
removal of primary tumor (Peeters et al., 2006). It has been shown that resection of 
primary tumors leads to loss of angiogenesis inhibition as primary tumors produce 
angiogenic and other growth factors important for growth of metastatic tumors (Li et al., 
2001b). Several clinical studies have supported the concept of metastatic dormancy 
imposed by the primary tumors (Fisher et al., 1983; Peeters et al., 2008). This is 
particularly important in the context of this study and can be a possibility. However, most 
of these studies have looked at the influence of primary tumor on the ‘growth of the 
metastatic tumor’ at the secondary sites whereas this study was focused more on 
understanding the initial steps of metastasis which include invasion, intravasation, 
survival in circulation and extravasation. It is possible that on reaching the metastatic site, 
survivin overexpressing cells will survive and proliferate more at the distant sites due to 
their anti-apoptotic and mitotic effect but this has not been extensively looked at in the 
present study.  
In our analysis, using gene silencing and functional blocking experiments, we 
have shown the importance of fibronectin in mediating tumor invasion in IAP expressing 
cells. This has physiological relevance as fibronectin has been extensively shown to be 
upregulated in a variety of tumors. A study by Gaggioli et. al (Gaggioli et al., 2007) 
showed that tumor derived fibronectin plays an important role in melanoma cell invasion. 
Additionally, gene expression profiling analysis has clearly shown a positive correlation 
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between enhanced fibronectin expression and acquisition of oncogenic and metastatic 
potential (Bittner et al., 2000; Clark et al., 2000). We have supporting evidence 
suggesting that fibronectin is one of the players in IAP-mediated tumor invasion. 
However, we lack the data that shows that exogenous presence of fibronectin is important 
for making a non-invasive cell type more invasive and metastatic. Based on our results, 
we believe that fibronectin is only one of the players and there are other parallel or 
converging pathways that might be important in IAP mediated tumor invasion, as 
survivin knockdown completely abolishes the ability of survivin overexpressing cells to 
invade (Figure 2-2 B) whereas in the same cell line, fibronectin silencing results only in 
50% reduction (Figure 2-9 B). 
Fibronectin, a high molecular glycoprotein is highly polymorphic and is known to 
exist in 20 different isoforms due to the alternate splicing of the primary transcript 
(Kornblihtt et al., 1984). The cellular fibronectin molecule has three regions that can be 
alternately spliced- EDA (extra domain A), EDB (extra domain B) and IIICS (type III 
homology connecting segment). Several studies have reported a differential pattern of 
alternately spliced isoforms in cancer tissues (Carnemolla et al., 1989; Oyama et al., 
1993). However, this study does not address whether IAPs modulate the expression of a 
particular isoform of fibronectin and which isoform of fibronectin is important for IAP 
mediated tumor invasion. A more detailed characterization of different isoforms of 
fibronectin in IAP expressing cells will be useful in resolving the issue.   
Moreover, in this study we have only looked at one of the cell adhesion 
molecules, fibronectin. Our data suggests a significant modulation of other ECM 
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components like collagens in IAP overexpressing cells (Figure 2-6A) although it has not 
been extensively looked at in the present study. Some of the cell adhesion molecules like 
VCAM-1(van de Stolpe et al., 1994), ICAM-1 (Iademarco et al., 1992), MMPs (He, 
1996) have also been shown to be NFκB targets hence further work needs to be 
performed to dissect the importance of other ECM components in mediating metastatic 
dissemination in IAP expressing cells.   
In our analysis, we have demonstrated that NFκB activation in IAP expressing 
cells leads to upregulation of fibronectin gene expression. A role of fibronectin as an 
NFκB responsive gene has been controversial in the only two papers that appear in 
literature (Lee et al., 2000; Lee et al., 2002). Our data strongly supports a positive 
regulation of fibronectin by NFκB using two independent approaches, reduction of 
fibronectin protein expression after siRNA targeting of the p65 subunit (Figure 3-2B) and 
enhanced expression of fibronectin after NFκB activation by TNFα (Fig. 3−2C), one of 
the known activators of the NFκB pathway. However, both these results show a 
modulation of fibronectin by activated NFκB only at the ‘protein level’ hence we require 
more direct evidence of fibronectin regulation by NFκB at the transcriptional level in 
survivin over-expressing cells in order to confirm our findings. 
 In the context of this study, there is growing evidence for a role of NFκB 
signaling in metastasis, largely associated with stimulation of epithelial-mesenchymal 
transition (EMT), expression of matrix metalloproteinase-9 (MMP-9), and repression of 
putative metastasis-suppressor genes, in vivo (Naugler and Karin, 2008).  In our 
experimental system, IAP-induced NFκB activation did not result in morphological 
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features of EMT, as judged by comparable expression of E-cadherin in MCF-7 or MCF-7 
SVV cells, or changes in MMP-2 or -9 levels. However, there is accumulating evidence 
that some of the transcription factors best characterized for their role in EMT like Snail 
(Nieto et al., 1994) can drive tumor progression in the absence of EMT  primarily by 
enhancing cell adhesion and migration (Barrallo-Gimeno and Nieto, 2005). Snail 
expression has been detected in an increasing number of carcinomas and associated with 
invasive ductal breast carcinomas (Blanco et al., 2002)and hepatocarcinomas (Sugimachi 
et al., 2003). A recent study (Haraguchi et al., 2008) showed that Snail regulates the 
expression of various ECM components which leads to enhanced cell migration and re-
attachment at the secondary site. This is particularly important in context to this study as 
IAP overexpressing show constitutive activation of NFκB and increased expression of 
fibronectin gene expression and Snail has been previously reported to be upregulated by 
NFκb activation (Julien et al., 2007). Hence, it will be interesting to explore if Snail is 
involved in mediating this program in IAP expressing cells. 
Fibronectin binds to their surface receptors integrins and leads to the 
phosphorylation and activation of cell motility kinases, FAK and Src. Integrin signaling 
has been shown to cross talk with the growth factor signaling. Emerging evidence show 
that growth factor mediated effects on cell proliferation, migration and adhesion depend 
on specific integrins (Eliceiri, 2001). Conversely, integrin mediated cell migration and 
invasion require growth factor stimulation. For example, αvβ5 bearing melanoma cells 
require IGF-1 pre-stimulation for metastasis (Brooks et al., 1997). Similarly other studies 
have shown a dependence of integrins on growth factor signaling to mediate the 
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downstream effects. It is possible that growth factor activation can be one of the ‘other 
converging pathways’ that might play an important role in tumor invasion of these IAP 
expressing cells. In support of this hypothesis, we have some preliminary data showing 
high expression of Epidermal Growth Factor receptor (EGFR) in breast cancer cell line 
overexpressing survivin (MCF-7 SVV). Additional experiments need to be performed to 
confirm the findings.  
Constitutive activation of NFκB has been shown in both solid tumors and 
hematological malignancies and hence it has been extensively targeted for anticancer 
therapy. Since NF-κB functions as an essential factor promoting cell survival of normal 
cells during stress and immune responses, it is logical to expect toxicity effects of NFκB 
inhibitors, which cannot be tolerated when designing effective cancer therapeutics. 
However, we have shown an ‘alternate’ pathway for activation of NFκB which requires 
survivin. Since survivin show differential expression in tumor cells as compared to 
normal cells, targeting survivin can be used as a powerful approach for specifically 
targeting NFκB activity in tumor cells. The major challenge that can be conceptualized 
when using this approach is the identification of NFκB driven tumors. However, 
advanced genomic technology has been successful in identifying a subset of diffuse large 
B-cell lymphoma (DLBCL) on the basis of NFκB gene signature  and preclinical studies 
have successfully validated NFκB as a therapeutic target in these lymphoma subtypes 
(Davis and Staudt, 2002). Hence, we can utilize the approach of gene expression profiling 
to identify other aggressive tumors that are NFκB-driven so that we can use survivin 
antagonists in a more meaningful manner. Even though survivin is not a surface protein 
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and lack catalytic activity, two of the important qualifications to be a ‘good therapeutic 
target’, several survivin antagonists tested in clinical trials have shown promising results. 
Some of these antagonists like YM155 are in advanced phase of clinical trials and we 
believe, with the present findings of survivin’s role upstream of gene expression, these 
antagonists can have broader clinical implications in both early and late stages of tumor 
progression. 
We have demonstrated that FAK and Src motility kinases are key mediators 
tumor metastasis in IAP expressing cells. Disruption of FAK activity using dominant 
negative mutant, FRNK and inhibition of Src phosphorylation using pharmacological 
inhibitorslike PP2 and SU6656 dramatically reduces the IAP mediated tumor invasion 
(Figure 2-12B, C). Additionally we have shown that phosphorylation and activation of 
Src at Tyr-416 in insulinoma cells (Figure 2-11E). IAP mediated Src activation can also 
be exploited for better targeting of metastatic tumors. Some of the commonly used Src 
inhibitors that are approved for treatment against chronic myelogenous leukemia (CML) 
and Acute Lymphoblastic leukemia (ALL) are Dasatinib (Bristol Meyers Squibb 
Oncology, Princeton, NY) , AZDSKI-606 (AstraZeneca, Macclesfield, United Kingdom) 
and  SKI606 (Wyeth Research, Pearl River, NY). They are also being tested for other 
solid tumors. Under in vitro conditions, all of these have been shown to suppress tumor 
invasion. Dasatinib has been shown to suppress invasion in head and neck squamous cell 
carcinomas (Johnson et al., 2005) and prevent the formation of liver metastasis in 
 orthotopic mouse model of pancreatic carcinoma (Trevino et al., 2006). AZD0530 has 
been shown to inhibit invasive ability.of tamoxifen breast cancer cells (Hiscox et al., 
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2006). Similarly SKI-606 has also been shown to inhibit tumor extravasation (Weis et al., 
2004). Even though all these studies show an important role of Src in the initial steps of 
metastasis, these Src inhibitors have always been tested when metastatic tumors have 
already been established. Based on our data, we believe that the Src inhibitors will be 
more effective as ‘adjuvant therapy ‘especially after the surgical resection of the primary 
tumor as it is possible that some of the tumor cells are leaked into the circulation during 
the surgical operation. Hence we can prevent the initiation of metastasis by treating these 
patients with Src inhibitors immediately after the surgical resection of the primary tumor.  
To conclude, the study presented in the thesis has both mechanistic insights and 
clinical implications. This work for the first time places survivin upstream of gene 
expression and unravels some of the essential components of IAP mediated metastasis 
which can be utilized for more targeted and effective anti-metastatic therapies among the 
others that are already being or intended to be investigated in future.  
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